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1 Abstract
New strategies are urgently needed to combat infectious diseases in an era of rising
antibiotic resistance. Furthermore, an emerging appreciation for the human microbiome’s role in
maintaining health motivates discovery of species-specific antibiotics that minimally disrupt our
native bacterial communities. Small molecule modifications to bacterial cell surfaces represent a
potentially rich source of new targets for next generation antibiotics, as these molecules mediate
virulence and evasion of the host immune response. Phosphocholine (PCho) is a rare cell surface
modification that contributes to virulence, and modifications with phosphonates like 2aminoethylphosphonate (AEP) are even more unusual and therefore provide opportunities for
species- and pathway-specific targeting.
Cytidylyltransferase enzymes are required to activate these unique substrates. The
cytidylyltransferase LicC was previously known to activate PCho through addition of a cytidine
monophosphate (CMP) moiety, and here we demonstrate that the homologous protein that we
have termed PntC activates AEP. PntC homologs and resulting cell-surface phosphonate
modifications have been identified across diverse phyla of bacteria. Among these bacterial
species are the known pathogens Atopobium rimae, Olsenella uli, Treponema denticola, and
Streptococcus pneumoniae. NMR analysis and continuous spectrophotometric assays were
performed to compare LicC from S. pneumoniae (Spn-LicC) to PntCs from the Gram positive A.
rimae (Ari-PntC) and Gram negative T. denticola (Tde-PntC). The results demonstrated that: (i)
PntC enzymes generate a previously unreported compound CMP-AEP; (ii) PntCs exhibit
specificity towards CTP and Mg2+; (iii) PntCs possess >400-fold preference for AEP over PCho,
while LicC exhibits a 200-fold preference for PCho over AEP; and (iv) LicC is capable of
accepting a range of larger substrates. These findings have provided insight into the activity and
versatility of these proteins to utilize uncommon molecular substrates, setting the stage for the
development of molecular probes and effective protein-specific inhibitors designed to halt the
overall phosphonate-tailoring pathway which could ultimately disrupt the ability of the pathogen
to confer virulence in a host.
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2 Statement of Work
The cloning of PntC from A. rimae into pET29 was completed by Jayne Kelso and Maddison
Bibby. EnzChek assays for Spn-LicC and Ari-PntC were performed by Kissa Batul. The cloning
of PntC from T. denticola into pET21 and the subsequent crystallization was completed by
Jacqueline Whiteside. The cloning of LicC from S. pneumoniae into pET29 was completed by
Rebecca Sullivan. All other work described in this thesis was completed by Kyle Rice. This
research has been submitted for publication and is currently under review at Nature
Communications (NCOMMS-18-36484-T).
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4 List of Tables
Table 1. Summary of kinetic constants and rates for three cytidylyltransferase enzymes.
a

b

Standard errors are included for data generated in this work. Substrate inhibition observed with
c

d

KS = 3.99±1.13 mM. Substrate inhibition observed with KS = 6.36±0.89 mM. ND, not
determined due to low activity.
Table 2. Structural comparison of all substrates tested.
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5 List of Figures
Figure 1. Diagram outlining a variety of phosphonate natural products. Within the circle are the compounds
known for involvement in phosphonate biosynthesis as well for providing a source of inorganic phosphate (4 is
an exception). Molecules outside of the circle are secondary metabolites. Figure taken from Horsman and
Zechel1.
Figure 2. Proposed biosynthetic logic for the phosphonoglycan (png) and lipopolysaccharide core (lic) in
selected pathogens. The step-wise reaction at the top illustrates the putative phosphonate pathway utilizing AEP
after being produced through the Ppm-catalyzed reaction. The step-wise reaction in the middle of the diagram
represents the canonical phosphocholine (PCho) pathway. The gene clusters at the bottom demonstrate that these
pathogens share a variety of proteins and catalytic functions.
Figure 3. Rooted phylogenetic tree of the bacterial species and respective phyla that have been determined to
possess mechanisms for phosphonate biosynthesis. The species in bold have been identified to contain a direct CP bond through RT-PCR analysis, with T. denticola and O. uli also showing evidence of this bond through NMR
analysis. The figure was created using NCBI Taxid ID’s.
Figure 4. Left: the canonical phosphocholine (PCho) tailoring pathway exhibited by S. pneumoniae. Right: the
putative phosphonate (Pn) tailoring pathway found in several bacterial species and phyla.
Figure 5. Genomic relationships between ppm and nucleotidyltransferase-encoding genes. (A) Left: 27716 nonredundant protein sequences were identified in NCBI’s refSeq prokaryotic genome database that matched the
PF13714 HMM, of which 905 were fused to other domains. Right: After filtering for the presence of the
characteristic Ppm motif (EDKXXXXXNS), 26231 presumed non-Ppm sequences were removed. Only 22 of
these removed sequences were fused to other domains. (B) Summary of the remaining 1485 predicted Ppm
proteins and inventory of fusion status: Ppm alone (red, 40.5%); PF12804, MobA-like NTP transferase
(NTP_transf_3; gray, 32.9%); PF01467, Cytidylyltransferase-like (CTP_transf_like; orange, 23.6%); not visible
are two genes matching PF02775 and PF02776 (both TPP binding domains), which corresponds to 0.1% of nonredundant Ppm proteins. The blue slice represents 42 triple fusion proteins (2.8% of all Ppm proteins) with Ppm
fused to both PF12804 and PF01467.
Figure 6. The overall structure of the LicC protein originating from S. pneumonia. The β-strands are coloured
green, and 7 β-strands form a central core β-sheet. The α-helices are coloured blue, and surround the core β-sheet.
The magnesium ion binds to the 218D, 107D and 216E residues, and are coloured in purple. (PDB ID: 1JYK)2.
Figure adapted from Whiteside3.
Figure 7. Active site interactions of LicC with phosphocholine, indicating many important active site residues
involved in binding. Black dashed lines indicate hydrogen bonds, salt bridges, and metal interactions. Green solid
lines show hydrophobic interactions (PDB ID: 1JYL)2. Figure adapted from Batul4.
Figure 8. Michaelis-Menten fit for the preliminary enzymatic rate of Ari-PntC at various concentrations of AEP
substrate. Figure adapted from Batul4.
Figure 9. The structure of the Tde-AEPT/PntC bifunctional enzyme originating from T. denticola. The PntC
domain (blue) contains a citidyltransferase active site (purple) with a bound magnesium ion (white). The AEPT
domain (red) contains an aminotransferase active site (orange) with a catalytic lysine residue (gold). The PntC
and AEPT domains are connected through a linker region (yellow). Figure adapted from Whiteside 3.
Figure 10. The structure of the active sites present in the Tde-AEPT/PntC bifunctional enzyme. A) The PntC
domain (blue) contains a citidyltransferase active site consisting of 15 residues (purple) with a magnesium ion
(white) bound to residues 104E, 106D, and 220E (dark blue) in an octahedral geometry. B) The AEPT domain
(red) contains an aminotransferase active site consisting of 7 residues (orange) with a catalytic 441K residue
(gold). Figure adapted from Whiteside3.
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Figure 11. SDS-PAGE gel images of the Ari-PntC, Spn-LicC and Tde-PntC proteins after IMAC purification.
Ari-PntC and Spn-LicC are visible at the correct and expected size of 31 kDa and Tde-PntC at 69 kDa. The lanes
from the IMAC purification are labelled as follows: Uninduced fraction (Un), Induced fraction (In), Raw extract
(RE), Flow through (FT), Wash 1 (W1), Wash 2 (W2), and Purified Protein (PP).
Figure 12. SDS-PAGE of Spn-LicC (lane 1), Tde-PntC (lane 2), Ari-PntC (lane 3), and Bio-Rad Precision Plus
Protein Standard (lane M).
Figure 13. HR-ESI-MS of CMP-AEP from the Ari-PntC reaction revealing the [M-H]- ion at m/z 429.0582
consistent with a molecular mass of 430.0655 for molecular formula C11H20N4O10P2 (calculated 430.0655).
Figure 14. 1H NMR (D2O, 400 MHz) spectra of CMP-AEP from the Ari-PntC reaction:  7.95 (d, 1H, H6, J =
7.6 Hz), 6.12 (d, 1H, H5, J = 7.6 Hz), 6.00 (d, 1H, H1’, J = 4.0 Hz), 4.82-4.18 (m, 5H, H2’, H3’, H4’, H5’), 3.29
(m, 2H, H2”), 2.15 (m, 2H, H1”).
Figure 15. 13C NMR (D2O, 100 MHz) spectra of CMP-AEP from the Ari-PntC reaction:  166.1 (C4), 157.7
(C2), 141.3 (C6), 96.6 (C5), 89.3 (C4’), 82.5 (C1’), 73.9 (C3’), 69.3 (C2’), 64.8 (C5’), 35.1 (C2’’), 26.1 (C1’’;
1
JCP = 130 Hz). Bottom spectrum represents commercial AEP alone.
Figure 16. 31P NMR (D2O, 121 MHz) spectra from the Ari-PntC reaction of (A) CMP-AEP alone and (B) with
phosphonoacetic acid (PnAc) and 2-ethylaminophosphonate (AEP). Using PnAc as the internal standard with a
reported chemical shift of 15.7,5 our measured chemical shifts of CMP-AEP:  11.4 (PA), -11.4 (PB), 3J = 25.6 Hz.
Figure 17. 31P NMR (121 MHz) spectra of the reaction mixture without substrate or enzyme. The 2 mM CTP
secondary substrate is responsible for the observed peaks.
Figure 18. 31P NMR (121 MHz) spectra of the Tde-PntC reaction with PEA and AMP (9.0 ppm). New peaks are
observed adjacent to the doublets at -5 and -10 ppm for the PEA reaction, and at -5.4 and 3.4 ppm for the AMP
reaction. 1-hour reactions of 10 µM PntC enzyme with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and
7 mM MgCl2, pH 8.0.
Figure 19. 31P NMR (121 MHz) spectra of the Ari-PntC reaction with PEA and AMP (9.0 ppm). New peaks are
observed adjacent to the doublets at -5 and -10 ppm for the PEA reaction, and at -5.5 and 3.4 ppm for the AMP
reaction. 1-hour reactions of 10 µM PntC enzyme with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and
7 mM MgCl2, pH 8.0.
Figure 20. 31P NMR (121 MHz) spectra of the Spn-LicC reaction with the synthesized Ethyl Azide (EtAz)
phosphonate substrate (17.2 ppm). New peaks are observed adjacent to the doublets at -5 and -10 ppm. 2.5-hour
reactions of 10 µM Spn-LicC enzyme with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and 7 mM
MgCl2, pH 8.0.
Figure 21. 31P NMR analysis of 1-hour reactions of 10 µM PntC enzyme with 1 mM AEP and 2 mM of CTP,
ATP, or GTP in 50 mM Tris-Cl and 7 mM MgCl2, pH 8.0. The reactions with the preferred CTP secondary
substrate shows activity for both Ari-PntC and Tde-PntC. The Tde-PntC reaction with ATP showed some
activity. No activity was seen using GTP as a secondary substrate.
Figure 22. Steady-state kinetic analysis of cytidylyltransferase activities of (A) Spn-LicC with AEP, (B) SpnLicC with PCho, (C) Ari-PntC with AEP, (D) Ari-PntC with PCho, and (E) Tde-PntC with AEP. Activity not
detected for Tde-PntC and PCho. Error bars show standard errors.

Figure 23. Proposed mechanism of PntC. (A) Electron density (Fo-Fc, 3.0 sigma) for the Tde-PntC:CMP-AEP
complex, highlighting interactions with phosphate in the site thought to be occupied by the PPi leaving group. (B)
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Mechanistic interpretation of the crystallographic data. The proposed ternary complex structure (top) with
extensive interactions stabilizing the PPi leaving group of CTP (blue). Nucleophilic attack of AEP (green)
generates a pentacoordinate phosphate intermediate or transition state possessing additional negative charge
stabilized by Lys25 (middle). Loss of PPi generates the CMP-AEP product bound in the active site (bottom) as
seen in the crystal structure in (A).
Figure 24. Chemical structure of the methyl (A) and ethyl phosphonate azide substrates synthesized by Edward
Schmidt (WLU).
Figure 25. Structural comparisons of Tde-PntC (top) and Spn-LicC (bottom) showing representative
conformations from molecular dynamics simulations. (A) Tde-PntC active site with cognate ligand CMP-AEP
and magnesium ions colored teal; non-cognate ligand CDPCho and magnesium ions are colored magenta. (B)
Spn-LicC active site showing the cognate ligand CDPCho and magnesium ion colored magenta; non-cognate
ligand CMP-AEP and magnesium are colored teal. Figure by Dr. Geoff Horsman.
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7 Introduction
7.1

Phosphonates: Organophosphonic Acids in Nature
Organophosphonic acids, also referred to more simply as phosphonates, are a unique
group of natural products that possess a characteristic carbon-phosphorus bond (C-P).
Consequently, these reduced phosphate molecules are more hydrolytically stable than the typical
organophosphate molecules found in nature. In addition to conferring resistance to hydrolytic
cleavage, a variety of organisms produce these compounds as secondary bioactive metabolites1,
as the phosphonyl group acts as a versatile mimic of other primary metabolites and enzymatic
transition/intermediate states. Moreover, enzymatic pathways have evolved to cleave the
characteristic C-P bond of phosphonate molecules in order to release a source of inorganic
phosphate that can be utilized by various organisms that reside in environments where this
metabolite is scarce or not naturally available1,6. To reinforce this statement, Clark et al.7
reported that as much as 20-30% of the available phosphorus in the world's oceans is comprised
of phosphonic acids.
Phosphorus is an essential nutrient to all living things and is involved in the synthesis of
many metabolites, nucleic acids, and phospholipids. Despite the fact that phosphorus is the 11th
most abundant element in the Earth’s crust6, most phosphate salts are highly insoluble and thus
phosphorus is rarely bioavailable to organisms and is often considered a limiting nutrient6. Thus,
the evolution of phosphonate biosynthetic mechanisms may have arisen to overcome the scarcity
of this nutrient, or these mechanisms may have been evolutionary progenitors of phosphates in
early Earth. However, the vast array of known phosphonate compounds also possess many other
biological functions that suggest the role of these chemicals encompasses much more than
simply increasing the bioavailability of scarce nutrients. Figure 1 represents a collection of
common phosphonate molecules found in nature. The molecules found within the main circle of
Figure 1 have been documented in literature to be involved in the biosynthesis of phosphonate
compounds, in addition to serving as a source of inorganic phosphate1. Among these molecules
is 2-aminoethylphosphonic acid (AEP), seen as molecule number 3 in Figure 1, which provided
the first connection to the role of phosphonate compounds in biology when the compound was
discovered in 1959 within the acid hydrolysate of rumen protozoa6,8.
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At that time, the presence of a direct C-P within living organisms was not understood and
the abundance of these moieties in other microorganisms was not known. Since then,

Figure 1. Diagram outlining a variety of phosphonate natural products. Within the circle are the compounds known for
involvement in phosphonate biosynthesis as well for providing a source of inorganic phosphate (4 is an exception).
Molecules outside of the circle are secondary metabolites. Figure taken from Horsman and Zechel1.

phosphonate molecules have been identified across diverse phyla of bacteria and many
compounds have been adopted by different industries for the development of therapeutics and
commercial products. For instance, fosfomycin (molecule 9 in Figure 1) is a common antibiotic
drug used to treat urinary infections, and phosphinothricin is the active ingredient in some
commercial herbicides1,9. As studies of these compounds and their respective biosynthetic
machinery has progressed, it is evident that phosphonates play an important role in nature. In
order to understand this intricate role, the diverse range of bacterial phyla associated with
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phosphonate biosynthesis must be identified and compared, and the associated enzymatic
pathways must be characterized and contrasted.
7.2

Metagenomic and Analytical Identification of Phosphonate-Tailoring Microorganisms
Bioinformatic studies of phosphonate precursors and the associated enzymes that catalyze

the formation of these molecules have concluded that phosphonate biosynthesis is in fact
common within the microbial world6. The only known precursor to phosphonate biosynthesis is
phosphoenolpyruvate (PEP), which is catalyzed by the enzyme PEP mutase (Ppm) to form
phosphonopyruvate (PnPy). PnPy can then undergo various transformations to produce different
phosphonates, such as AEP. The sequence diversity of PEP mutases in nature further suggests
that many bacteria are able to utilize this machinery in order to modify or tailor phosphonate
molecules to polysaccharides and lipids on the microbial cell surface6,10. It is assumed that this
cell-surface phosphonate modification is much less common in bacterial species than the
naturally occurring PCho modifications, nevertheless, it is still easy to identify this feature when
analyzing distinct bacterial phyla.
Using the ppm gene as a molecular marker, Yu et al.6 discovered that approximately 5%
of sequenced bacterial genomes and 7% of genome equivalents in metagenomic datasets carry
the ppm homolog. Through these metagenomic studies it was discovered that 9 of the 33
bacterial phyla contain species that encode the ppm gene6. These species are found most
abundantly in the Proteobacteria, Bacteroidetes, Firmicutes, Actinobacteria, and Spirochaetes
phyla, specifically, a large portion of bacterial species from the genera Burkholderia,
Selenomonas, and Nitrosococcus appear to possess phosphonate biosynthetic capabilities. 77 of
82 sequenced Burkholderia genomes, 8 of 9 sequenced Selenomonas genomes, and all 4
sequenced Nitrosococcus genomes were found to include at least one ppm gene6. The
Cyanobacteria have also been documented as an abundant Ppm-containing genus in marine
environments. Not only is the ppm gene and associated homologs highly conserved amongst
bacterial species, but some of the surrounding genes are also conserved, allowing for elucidation
of the biosynthetic phosphonate products formed6,10. Figure 2 illustrates the reaction catalyzed
initially by Ppm, as well as three bacterial species and the associated operons which display the
gene clusters associated with the putative phosphonyl tailoring (pnt) machinery and the canonical
lipopolysaccharide core (lic) pathway that will be addressed in Section 2.3. From these gene
clusters it is evident that many of the same enzymes are encoded by different bacteria, and these
14

proteins are all used to facilitate the same type of enzymatic cascade in which a phosphate or
phosphonate molecule is tailored to the cell-surface through chemical linkage to a polysaccharide
or lipopolysaccharide.

Figure 2. Proposed biosynthetic logic for the phosphonyl tailoring (pnt) and lipopolysaccharide core (lic) in
selected pathogens. The step-wise reaction at the top illustrates the putative phosphonate pathway utilizing AEP
after being produced through the Ppm-catalyzed reaction. The step-wise reaction in the middle of the diagram
represents the canonical phosphocholine (PCho) pathway. The gene clusters at the bottom demonstrate that
these pathogens share a variety of proteins and catalytic functions. PngC=PntC and ChoP=PCho in this figure.
Figure created by Dr. Geoff Horsman, Wilfrid Laurier University.

Recently, with collaborators our lab identified C-P bonds present in a few bacterial species
from different phyla using solid-state NMR, which suggests that NMR analysis may be a good
approach to explore further when attempting to identify this modification. This data has been
compiled and is presented in the rooted phylogenetic tree in Figure 3, along with other bacteria
that contain phosphonate machinery, computed from NCBI Taxid ID’s. Evidently, phosphonatetailoring machinery is present in an abundance of microorganisms and used to display these
unique molecules on the outer cell surface, yet the question remains as to why this modification
has evolved to become so familiar in nature and to what advantage does this process confer to
the host?
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Figure 3. Phylogenetic tree of the bacterial species and respective phyla that have been determined to possess
mechanisms for phosphonate biosynthesis. The species in bold have been identified to contain a direct C-P bond
through RT-PCR analysis, with T. denticola and O. uli also showing evidence of this bond through NMR analysis. The
figure was created using NCBI Taxid ID’s and has been adapted from Bartlett et al43.
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7.3 Streptococcus pneumoniae: The Canonical Pathway
To understand why cell-surface phosphonate modifications are widespread among bacteria,
the specific enzymatic pathways of a variety of bacteria must be compared and contrasted.
Among these bacteria is the well-studied pathogen Streptococcus pneumoniae, which utilizes
several enzymes to tailor phosphocholine to the cell-surface through linkage to a polysaccharide
group on teichoic and lipoteichoic acids2,11. This modification has been documented to be
required for virulence in S. pneumoniae, playing an important role in the initial attachment of the
pathogen to the upper respiratory tract via the platelet-activating factor (PAF) receptor,
expressed on host cells12,13. The role of choline in pathogenicity is not confined to S.
pneumoniae, but also plays a role in other bacteria such as Hemophilus influenzae, Pseudomonas
aeruginosa and Neisseria gonorrhoaea14.
In order to facilitate the attachment of phosphocholine (PCho) to the lipopolysaccharides
on the cell-surface, the PCho molecule must be acquired from the host to begin crafting the PCho
substrate12. A choline permease protein LicB facilitates the transport of choline into the bacterial
cell before a choline kinase, LicA, phosphorylates the molecule to form PCho using the
nucleotide ATP as a secondary substrate. From here, the LicC cytidylyltransferase enzyme
utilizes PCho as a substrate, Mg2+ metal cations and the nucleotide CTP as a secondary substrate
to form CDP-choline. This is the final substrate utilized by the phosphotransferase LicD to be
attached to a sugar and exported to the outer membrane. This pathway can be seen in Figure 4.
In a study by Kharat and Tomasz13, the licA, licB, and licC genes were inactivated through
genetic cloning and PCR techniques to produce mutant bacterial strains that lack the ability to
uptake and modify choline. The results of this research concluded that these S. pneumoniae
mutants exhibited a dramatic reduction in virulence when inoculated into the peritoneal cavity of
CD1 mice and a line of pre-isolated human nasopharyngeal cells. The choline-lacking bacteria
displayed a loss of ability to adhere to human nasopharyngeal cells and were also completely
blocked from invading these cells, while the bacteria was rapidly eliminated from the nasal
passages of mice13. The virulence was claimed to be reduced to a level that approaches that of a
capsule-free pneumococcal pathogen. It was concluded that choline is not necessary for the
production of the pneumococcal capsule or growth of the bacteria as a whole, but has an
irreplaceable function associated with virulence12,13.
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Although inactivation or deletion of the licC enzyme altogether displays a dramatic
decrease in virulence, it does not provide direct information on the function of the protein.
However, research by Zeng et al15 in which a truncated licC enzyme was obtained and examined
in vitro provides further information regarding the functions of this protein. This 78-bp
truncation at the C-terminus of licC was used to create a viable mutant in which enzymatic
activity and virulence could be observed. Using a firefly luciferase assay it was determined that
the mutant S. pneumoniae strain had decreased cytidylyltransferase activity by the licC enzyme
but remained viable. A significant result was the finding that PCho on the cell surface was
decreased, and the choline binding proteins were impaired, leading to attenuated virulence in the
mutant15. Furthermore, the mutation attenuated the adhesion and invasion of S. pneumoniae to
epithelial cells by 72% and 80%, respectively15. These findings suggest that the C-terminus of
the licC protein would serve as a promising target for drug design due to the evident link
between the C-terminus of the protein and the decrease in PCho metabolism which is an essential
mechanism behind the virulence exhibited by the native S. pneumoniae pathogen. This research
further supports the claim that the licC enzymes play a crucial role in pneumococcal infection
and reinforces the need for further research into the characterization and inhibition of these
cytidylyltransferases.
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pathway found in several bacterial species and phyla. PngC=PntC in this
figure. Figure created by Dr. Geoff Horsman, Wilfrid Laurier University.

AEP. This is the initial substrate for the pathway. Since AEP is acquired endogenously, bacteria
that typically utilize the PCho pathway may be able to take advantage of this alternate route of
synthesis when environmental sources of choline are scarce or unavailable. Furthermore, the
hydrolytic stability of the direct C-P bond may in fact prolong microbial infection of pathogens
by resisting degradation. Thus, it is hypothesized that this putative phosphonate-tailoring
pathway also plays a role in conferring virulence to the bacterial host due to the great similarities
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between pathways and the structural similarities of the molecules attached to the cell-surface.
This thesis focuses on the homologous cytidylyltransferase enzyme that has been termed PntC, in
comparison to the canonical LicC enzyme. A great deal of research has been conducted by
members of the Horsman Lab and other colleagues to analyze and characterize the many variants
of these enzymes among different bacterial species to ultimately allude to their role in nature and
pave the way for the design of pathway- or enzyme-specific inhibitors to potentially eliminate
the cell-surface phosphonate modifications and disrupt virulence.

7.4 Characterization of LicC/PntC Cytidylyltransferases
Bioinformatic studies have revealed an apparent predominance of the PntC type enzymes
in phosphonate biosynthesis. To identify enzymes commonly associated with Ppm, a colleague
from the Horsman group assessed Ppm protein sequences for the presence of fused domains. The
reason for identifying active Ppm fusion proteins was recently established in the Streptomyces
wedmorensis fosfomycin biosynthetic pathway. The Ppm enzyme Fom1 possesses an Nterminally fused cytidylyltransferase (CyTase) domain catalyzing cytidylyltransfer from CTP to
hydroxyethylphosphonate (HEP) to generate CMP-HEP16. Interested by this example, a Ppm
fusion inventory was created (Figure 5). From the NCBI refSeq database containing 113,086
genomes, 146,399 proteins were identified in 72,350 genomes matching the hidden Markov
model (HMM) for the Ppm/isocitrate lyase Pfam family (PF13714).17 After filtering out identical
sequences, 27,716 non-redundant protein sequences matching PF13714 remained, of which only
905 (3.3%) were fused to another Pfam domain (Figure 5A). Of the 27,716 total sequences, only
1,485 possessed the Ppm-specific EDKXXXXXNS motif 6. Surprisingly, almost all fusions (883
out of 905) possessed this motif, indicating that 59.5% of Ppm enzymes are fused to other
domains. Fusions of Ppm to the cytidylyltransferase-like domain was discovered to encompass
23.6% of the fusion proteins,17 indicating that cytidylyltransferases and PntC-like enzymes are
predominant in phosphonate biosynthesis among many bacterial species.
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Figure 5. Genomic relationships between ppm and nucleotidyltransferase-encoding genes. (A) Left:
27716 non-redundant protein sequences were identified in NCBI’s refSeq prokaryotic genome
database
that matched the PF13714 HMM, of which 905 were fused to other domains. Right: 1.0
After
3
filtering for the presence of the characteristic Ppm motif (EDKXXXXXNS), 26231 presumed nonPpm sequences were removed. Only 22 of these removed sequences were fused to other domains. (B)
Summary of the remaining 1485 predicted Ppm proteins and inventory of fusion status: Ppm alone
(red, 40.5%); PF12804, MobA-like NTP transferase (NTP_transf_3; gray, 32.9%); PF01467,
0.8
Cytidylyltransferase-like (CTP_transf_like;
orange, 23.6%); not visible are two genes
1.0 matching
900
PF02775 and PF02776 (both TPP binding domains), which corresponds to 0.1% of non-redundant
Ppm
42 triple fusion proteins (2.8% of all Ppm proteins) with Ppm
90
2 proteins. The blue slice represents
0.8
fused to both PF12804 and PF01467. Figure created by Dr. Geoff Horsman.
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the eukaryotic pathway serves to create phosphatidylcholine – a major phospholipid component
of cellular membranes and also a pulmonary surfactant.
The first of these enzymes to be purified was the eukaryotic CTP:phosphocholine
cytidylyltransferase (CCT) found in the liver of rats. Through much experimentation and
difficulty, the first enzyme was purified through the addition of lipids and detergents to the
soluble fraction of the rat liver, therefore treating the soluble fraction as if it were a membrane
enzyme18,20. The activity of this enzyme yielded a Km value of approximately 0.29 mM for CTP
and 0.14 mM for PCho, with a catalytic efficiency (kcat/Km) of 170 s-1 mM-1 for the conversion of
phosphocholine to CDP-choline18,20. Furthermore, a conserved HXGH sequence was identified
within the catalytic regions of the cytidylyltransferase enzymes in various organisms, regardless
of the preferred substrate for each protein. Mutation of the Gly-91 residue of the HXGH
sequence in the rat cytidylyltransferase to a more hydrophilic serine residue demonstrated a 4fold reduction in Vmax and a 25-fold increase in the Km for CTP21, while individual mutation of
the histidine residues reduced the kcat values to less than 0.1% of the wild-type activity,
indicating that the histidine residues play a role in stabilizing the intermediate formed22.

7.4.1 Streptococcus pneumoniae
As mentioned previously, S.
pneumoniae possess the licC gene
which

encodes

for

the

CTP:phosphocholine
cytidylyltransferase (CCT), or LicC,
enzyme involved in the activation of
PCho. Although the function of the
enzymes are the same, CCT found in
bacteria shares minimal sequence
similarity to the CCT found in
eukaryotes, except for within the
catalytic
Figure 6. The overall structure of the LicC protein originating
from S. pneumonia. The β-strands are coloured green, and 7 βstrands form a central core β-sheet. The α-helices are coloured
blue, and surround the core β-sheet. The magnesium ion binds
to the 218D, 107D and 216E residues, and are coloured in
purple. (PDB ID: 1JYK)2. Figure adapted from Whiteside3.

conserved

site,

specifically

the

region18.

The

HXGH
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overall enzymatic pathway is utilized to display PCho on the cell-surface through covalent
attachment to the sugar groups of teichoic acids and lipoteichoic acids, ultimately contributing to
the virulence of the pneumococcal
species2,11–14,18. The structure of the
LicC enzyme from S. pneumoniae (SpnLicC) was solved by Kwak et al.2 and is
presented in Figure 6. From this
structure it is evident that a mixed
seven-stranded β-sheet is flanked by
three α-helices on either side and the
218D, 107D and 216E residues in SpnLicC bind to a magnesium ion in an
octahedral

molecular

geometry2.

Magnesium is required to neutralize the
charge in the active site pocket and is
essential for catalytic efficiency. The
active site interactions of Spn-LicC with

Figure 7. Active site interactions of LicC with
phosphocholine, indicating many important active site
residues involved in binding. Black dashed lines indicate
hydrogen bonds, salt bridges, and metal interactions. Green
solid lines show hydrophobic interactions (PDB ID: 1JYL) 2.
Figure adapted from Batul4.

the phosphocholine substrate can be
seen in Figure 7. The negatively charged residues lining the active site pocket of Spn-LicC
include Asp105, Asp107, Glu135, Asp192, Glu216, and Asp218. Among these residues, Asp107 and
Glu216 are conserved within the NTP transferase family members2 (Section 2.4.2.1). The O-2
oxygen of the cytosine base is hydrogen-bonded to the amide nitrogen of Ala13 and the hydroxyl
group of Ser90, and the N-4 nitrogen of the base is hydrogen-bonded to the carbonyl oxygen
atoms of Tyr82 and Tyr85 11. Campbell and Kent11 were among the first to characterize the SpnLicC protein, discovering that the pure enzyme possesses Km values of 890 ± 240 μM for CTP,
and 390 ± 170 μM for PCho, while the kcat value was determined to be 17.5 ± 4.0 s-1. Rock et
al.14 reported that the Km for CTP was 133 μM and that for PCho it was 83 μM. The Km values
are comparable to those determined for the CCT enzyme in the liver of recombinant rats 20,23 and
also in Saccharomyces cerevisiae24. Batul4 also determined experimental kinetic values using the
EnzChek® pyrophosphate assay for Spn-LicC. Specifically, the Km and kcat values for Spn-LicC
towards PCho were 0.020 ± 0.011 mM and 1.52 ± 0.243 s-1 respectively, yielding kcat/Km of 77.9
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M-1 s-1. In contrast, the Km value for Spn-LicC towards AEP was 0.318 ± 0.126 mM and the kcat
was 0.722 ± 0.053 s-1, yielding kcat/Km of 2.27 M-1 s-1 and revealing a 34-fold preference for
PCho4.
7.4.1.1 The NTP Transferase Family
The NTP transferase family consists of a group of nucleotidyltransferase enzymes that
utilize the nucleotides ATP, CTP, GTP, TTP, and UTP. A common reaction catalyzed by these
enzymes is the transfer of a nucleoside monophosphate (NMP) substituent containing one of the
five nitrogenous bases to another substrate, such as a DNA or RNA strand in the event of cellular
DNA/RNA repair, or to sugar moieties for the development of cell wall components. Members
of this family that aid in the development of the cell wall primarily activate sugars by
transferring the NMP moiety to a phosphorylated acceptor substrate concomitant with the release
of pyrophosphate2.
This superfamily of proteins share a highly conserved sequence of residues within the
amino terminus; KAX5GXGTRX6–9K2,14. The LicC cytidylyltransferase enzyme from S.
pneumoniae was found to possess residues within the N-terminus that share similarity with the
conserved sequence, as well as with two other known NTP transferase family members from
Escherichia coli and Pseudomonas aeruginosa2,14. E. coli possess an N-acetylglucosamine 1phosphate uridylyltransferase (GlmU), which is a cytoplasmic bifunctional enzyme involved in
the biosynthesis of the nucleotide-activated UDP-GlcNAc. This molecule is an essential
precursor for the biosynthetic pathways of peptidoglycan and other components in bacteria25. P.
aeruginosa contains a glucose-1-phosphate thymidylyltransferase (RmlA), which catalyzes the
formation of deoxythymidine diphosphate (dTDP)-ʟ-rhamnose. dTDP-ʟ-rhamnose is another
important component of the cell wall for many microorganisms26. The NMP transferase domains
of these three enzymes have similar overall folding, and they share several key residues involved
in substrate binding and/or catalysis, such as Gly14, Arg18, and Lys28 (LicC numbering) in the
signature sequence2. Evidently, the GlmU and RmlA enzymes from the NTP transferase
superfamily play a crucial role in the development of the bacterial cell wall. The LicC and the
putative PntC enzymes are also involved in modifications to the cell-surface of bacteria, which
explains why these cytidylyltransferase proteins share such similarity to the conserved Nterminal sequences of the NTP transferase family as a whole and to the GlmU and RmlA
enzymes specifically.
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7.4.2 Atopobium rimae
A known bacteria of the oral microbiome, A. rimae is a gram-positive facultative anaerobe.
The cytidylyltransferase we have termed Ari-PntC was one of the first PntC enzymes to undergo

Figure 8. Michaelis-Menten fit for the preliminary enzymatic rate of Ari-PntC at various concentrations of AEP
substrate. Figure adapted from Batul4.

characterization in the Horsman Lab4, in parallel with the canonical LicC cytidylyltransferase
found in S. pneumoniae. Unfortunately, a crystal structure of Ari-PntC has yet to be acquired and
thus no structural data is available. Nevertheless, initial kinetic data for this cytidylyltransferase
has been acquired after successful expression and purification of the 31 kDa protein. The
EnzChek® pyrophosphate assay was used to determine the kinetic parameters for Ari-PntC,
where the AEP substrate gave a Km value of 0.011 ± 0.001 mM and a kcat value of 2.72 ± 0.079 s1

, yielding a kcat/Km of 239 M-1 s-1. Not surprisingly, Ari-PntC exhibits a 320-fold preference for

the AEP substrate over the PCho substrate. A plot of the enzymatic rate versus substrate
concentration (Michaelis-Menten fit) can be seen in Figure 8. These kinetic parameters can be
compared to the newly obtained values from the current research found in Table 1. Differences
among the kinetic parameters can be accounted to the nature of the coupled assay and the
necessary incubation periods of the reagents that can cause fluctuation in the enzymatic rates
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calculated. Nevertheless, the overall trends and substrate preferences remain the same between
the preliminary kinetic parameters and those presented in this research.
7.4.3 Treponema denticola
T. denticola is a gram-negative anaerobic bacterium and known oral pathogen,
contributing to periodontal disease and dental caries. This bacteria is one of three species of
pathogens that synergistically co-inhabit the human oral microbiome to form what is known as
the ‘red complex’ and contributes a great deal to late biofilm development and the onset of
infection27,28. Recently, the cytidylyltransferase present within T. denticola was expressed and
purified, and the structure of the 69 kDa protein was solved through X-ray crystallography by
Whiteside3. Interestingly, the tde1415 gene encodes for a bifunctional protein, with one domain
catalyzing the reaction of phosphonoacetaldehyde (PnAA) to AEP, and the other domain
catalyzing the reaction of AEP to CMP-AEP. For this reason the enzyme has been termed TdeAEPT/PntC, where AEPT stands for 2-aminoethylphosphonate transaminase (Figure 2). The
crystal structure for this enzyme is seen in Figure 9. The active site in the PntC domain consists
of 15 residues (8L, 9A, 10G, 11G, 84G, 85S, 88T, 105S, 106D, 104E, 135G, 194E, 196E, 220E,
222D) and a magnesium ion, whereas the active site present in the AEPT domain consists of 7
residues (314G, 315T, 318D, 386V, 415D, 418S, 438T) and a catalytic lysine residue (441K)3.
The structure of each active site is present in Figure 10. For simplicity, the PntC domain of T.
denticola will be referred to as Tde-PntC
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Figure 9. The structure of the Tde-AEPT/PntC bifunctional enzyme originating from T. denticola. The PntC
domain (blue) contains a citidyltransferase active site (purple) with a bound magnesium ion (white). The AEPT
domain (red) contains an aminotransferase active site (orange) with a catalytic lysine residue (gold). The PntC
and AEPT domains are connected through a linker region (yellow). Figure adapted from Whiteside 3.
.

Furthermore, many bacteria such as O. uli and T. denticola possess lic genes encoding
proteins such as a LicAC fusion. This bifunctional enzyme indicates that the organism is also
able to utilize the canonical PCho-tailoring pathway29. The LicAC protein would theoretically
utilize both the choline kinase function of LicA, in concert with the cytidylyltransferase action of
LicC. The presence of both the lic and pnt genes within a single genome suggests the bacterium
is able to utilize both the canonical and putative pathways, potentially switching the mechanism
of polysaccharide modification from the former to the latter when exogenous sources of choline
are scarce, or when virulence is to be prolonged through the modification of phosphonate
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A)

B)

Figure 10. The structure of the active sites present in the Tde-AEPT/PntC bifunctional enzyme. A) The PntC
domain (blue) contains a citidyltransferase active site consisting of 15 residues (purple) with a magnesium ion
(white) bound to residues 104E, 106D, and 220E (dark blue) in an octahedral geometry. B) The AEPT domain
(red) contains an aminotransferase active site consisting of 7 residues (orange) with a catalytic 441K residue
(gold). Figure adapted from Whiteside3.

moieties. Bifunctional enzymes such as LicAC and AEPT/PntC are also noteworthy due to the
potential of substrate channeling between the two domains. This would increase catalytic
efficiency compared to two individual enzymes accomplishing the same two reactions
separately, and may also aid the bacteria in quickly adapting to environmental changes through
rapid phosphonoglycan modification3.

7.5 Reducing the Selective Pressure towards Antibiotic Resistance
One of the largest threats to public health today is the rise of antibiotic resistance due, in
part, to the over-use of broad-spectrum therapeutics30. Many of the bacteria that reside in the
human body are commensal, and provide a benefit to health. The use of antibiotic drugs not only
kills the pathogen, but disrupts the normal microflora in the human body, causing an imbalance
in the bacterial species and/or changing the presence of certain bacterial populations in the body
over time. The small subset of bacterial species that survive must possess an advantage over the
other populations, and now have the space and nutrients available to replicate and transfer the
ability to resist antibiotic treatments to subsequent generations. The current research aims to set
the stage for the development of target- or pathway-specific inhibitors that can be used against a
variety of pathogens. Thus, by effectively targeting the cell-surface modifications of these
pathogens, the potential for virulence can be reduced without killing the organism, weakening
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the selective pressure on pathogens to acquire resistance and contributing to the fight against
antibiotic resistance.

8 Thesis Statement
Based on preliminary results and previous research, it is hypothesized that PntCs from both
T. denticola and A. rimae will exhibit the highest specificity for AEP as a substrate and will form
the CMP-AEP product, compared to PCho and other similar phosphonate substrates. The Km and
kcat values for Tde-PntC are predicted to be similar to the values acquired previously for AriPntC4. We also hypothesize that Spn-LicC will tolerate a larger range of substrates, since PCho
is larger than AEP. Mutation of catalytic residues on either the Spn-LicC or Tde-PntC enzymes
should reduce overall activity, but will aid in determining which residues are most essential to
function. Mutagenesis experiments will aid in allowing these enzymes to be more accepting of
non-preferred substrates and provide the first information available as to whether an azidecontaining substrate can be used by these proteins to potentially act as a molecular probe.

8.1 Specific Aims
1. Kinetic characterization of various PntC enzymes. Continuous kinetic assays and
NMR detection techniques will be performed to gather initial Km and kcat values for the
PntC enzymes from A. rimae and T. denticola as well as for the LicC enzyme from S.
pneumoniae. PCho and AEP are the preferred substrates and will be used to gather initial
kinetic constants. Substrate specificity will be tested towards different phosphonates and
phosphates, including PCho/AEP, phosphoethanolamine, aminomethylphosphonate, and
glyphosate. Various NTPs and metals will also be tested to determine the effect on
activity. Data gathered will be compared to data acquired previously and literature values
when applicable.
2. Structural confirmation of the enzymatic products. 1H,

13

C, and

31

P NMR analysis

will be performed on the CMP-AEP product produced to compare to mass spectrometry
data gathered previously, while any products formed through the reactions with an
alternate substrate will be collected to gather initial structural data through NMR.
3. Structural comparison of PntC Enzymes, mutagenesis, and introduction of an azide
substrate. Tde-PntC and Spn-LicC have been crystallized in the past and the structure of
each protein has been solved. Analysis of the conserved residues within the active and
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catalytic sites as well as multiple sequence alignments will provide insight into the
mechanism of the protein, while also providing suggestions as to which residues to
mutate in order to make each protein more accepting of non-preferred substrates. A novel
azide-containing substrate will be tested in order to determine if any activity is present
and if this type of substrate could be used as a potential molecular probe for identifying
phosphonate-tailoring bacteria.

9 Materials and Methods
9.1 Materials Used
9.1.1 Mutagenesis, Expression, and Purification of Ari-PntC, Tde-PntC, and Spn-LicC
The spn-licC gene was purchased from BioBasic Canada (Markham, ON) in the pET57
vector to include the N-terminal sequence MGSSH6SSGLVPRGSH prior to the N-terminal
methionine residue and preserve the exact sequence of the previously characterized enzyme. The
spn-licC gene was cloned as an NdeI/XhoI fragment into pET29. The ari1348 gene was
purchased codon-optimized for E. coli from BioBasic in the pET28a vector and subcloned as an
NdeI/NotI fragment into pET29. The resulting expression construct was designed to generate Cterminal His6-tagged Ari-PntC protein. The tde1415 gene was purchased from BioBasic in
pET28a and subcloned without its stop codon as a NdeI/NotI fragment into pET21b to produce
C-terminal histidine6-tagged protein of the bifunctional AEPT/PntC protein. PCR buffers and
polymerases were purchased from Bio Basic (Markham, ON). A C1000 Touch Thermal Cycler
was purchased from BioRad (Mississauga, ON). Wizard SV Gel and PCR Clean-Up System
were purchased from Promega (Madison, WI). Agarose gel electrophoresis was performed using
a gel apparatus and power source from VWR (Mississauga, ON). A Gel Doc EZ imager was
used for gel imaging and purchased from BioRad (Mississauga, ON). The PureYield Plasmid
Miniprep system was purchased from Promega (Madison, WI). DNA sequencing was completed
at the Hospital for Sick Children at the Centre for Applied Genomics (Toronto, ON). The pGem
T-Easy Vector System was purchased from Promega (Madison, WI). Escherichia coli DH5a and
BL21 were purchased from Novagen (Madison, WI). The pET21, pET28, and pET29 vectors
used for cloning were purchased from Novagen (Madison, WI). NdeI and XhoI restriction
enzymes were purchased from ThermoFisher Scientific (Waltham, MA). The Heroes Multifuge
X1R centrifuge was purchased from ThermoFisher Scientific (Waltham, MA). High-speed
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centrifuge tubes and low speed 500 mL tubes were purchased from ThermoFisher Scientific
(Waltham, MA). The Q-Sonica Q125 sonic processor was used for sonication of cells (Newton,
CT). Tris buffer, and the kanamycin and ampicillin antibiotics were purchased from Amresco
(Cleveland, OH). Nickel resin was purchased from Qiagen (Toronto, ON). Protein purification
was performed over a 5 mL HiTrap Q FF anion exchange chromatography column purchased
from GE Healthcare (Chicago, IL) using a BioRad NGC FPLC system. Ultracentrifugal devices
were purchased from Pall Corporations (Port Washington, NY). PD-10 columns were purchased
from BioRad (Mississauga, ON). SDS-PAGE gels were cast using TGX Stain Free FastCast
Acrylamide Kit 12% purchased from Bio Rad (Mississauga, ON). Protein and DNA standard
ladders were purchased from BioRad (Mississauga, ON).
9.1.2 Pyrophosphate Detection Assay
The EnzCheck® Pyrophosphate Assay Kit (E-6645) was purchased from ThermoFisher
Scientific (Waltham, MA). xMark Microplate Absorbance Spectrophotometer was purchased
from Bio-Rad (Mississauga, ON) and was used to analyze the results. CTP was purchased from
ThermoScientific (Waltham, MA) and MgCl2 was purchased from Amresco (Cleveland, OH).
Chelax resin, AEP, and other phosphonate substrates were purchased from Sigma Aldrich (St.
Louis, MO).
9.1.3 NMR Analysis
NMR spectra were recorded on an Agilent DD2 operating at 400 MHz for 1H and 100 MHz
for

13

C. A Varian Unity Inova operating at 121 MHz was used to record
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P NMR spectra.

Deuterated solvents were purchased from Sigma Aldrich.

9.2 Methods
9.2.1 Protein production
Plasmids were transformed into E. coli BL21(DE3) and plated on the LB agar plates
containing the appropriate antibiotic (kanamycin for pET28/29 and ampicillin for pET21). Single
colonies were picked into ~5 mL and grown overnight at 37 °C in LB supplemented with
antibiotic, 1 mL of which was then transferred to 50 mL LB supplemented with antibiotic. After
overnight growth at 37°C, 1 L batches of fresh LB were inoculated with 10 mL of the overnight
culture and incubated at 37°C and 220 rpm. At OD600 ~0.5, cultures were cooled on ice to
~18°C, supplemented with 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG), and then
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incubated overnight at 18 °C. Cells were harvested by 15 min centrifugation at 4 °C and 4,000 x
g and subsequent steps were performed on ice. From 1 L of culture, the resulting pellet was
resuspended in cell lysis buffer (50 mL, 0.73 M sucrose, 50 mM Tris-Cl, pH 8.0) and
supplemented with 4 mM dithiothreitol (DTT). 1 mg of egg white lysozyme was added and
stirred for 10 min, after which 50 mL of deoxycholate solution was added and the solution was
stirred until it became viscous (~10 min). The deoxycholate solution contained 24 mM
deoxycholate sodium salt, 0.5% v/v Triton X-100, 0.3 M NaCl, 20 mM Tris-Cl, pH 8.0.. A
solution of 1 M MgCl2 (500 μL) was added together with deoxyribonuclease I from bovine
pancreas and stirred at room temperature until the solution became less viscous. The solution
was then centrifuged at high speed (14,000 x g) for 20 min at 4 °C to afford clarified supernatant
raw extract.
9.2.2 Protein purification
To each 50 mL of raw extract was added 2 mL of Ni-NTA agarose affinity resin and
gently shaken at 4 °C and 120 rpm for 40 min. The resin was then washed and eluted with (x
column volumes or mLs) 20 and 250 mM imidazole, respectively, in 50 mM Tris-Cl buffer pH
8.0 containing 300 mM NaCl. Eluted protein (10 mL) was dialyzed overnight at 4 °C in 50 mM
Tris-Cl, pH 8.0 using MWCO 3,500 dialysis tubing, and then run over the GE Hi-Trap™ Q FF
anion exchange column attached to the FPLC system. After isocratic flow in 50 mM Tris-Cl (pH
8.0) for 2.5 column volumes, a linear gradient from 0 to 700 mM NaCl was performed over 18
column volumes. Tde-PntC eluted at ~120 mM NaCl, and Ari-PntC and Spn-LicC eluted at ~250
mM NaCl. Pooled FPLC fractions were concentrated to ~2 mL by ultrafiltration using 10 kDa
MWCO centrifugation then desalted into Tris-Cl pH 8.0 buffer using PD-10 columns. The
desalted protein was concentrated to ~200 μL by ultrafiltration, then either used immediately or
frozen as beads in liquid nitrogen for storage at -80 °C until further use.
9.2.3 Pyrophosphate Detection Assay
The EnzCheck® Pyrophosphate Assay Kit was used to determine the activity of SpnLicC, Ari-PntC, and Tde-PntC. Each reaction was kept to a total volume of 100 μl and performed
in triplicate in 96-well microplates. The reaction components were split between 2 wells, one
well contained the substrate and enzyme, while the other well contained CTP. Well 1 contained
0.5 μl (1U) purine nucleoside phosphorylase (PNP), 0.5 μl (0.03U) inorganic pyrophosphatase
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(IPP), 10 μl (0.2 mM) 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG), 2.5 μl 20X
reaction buffer, 16 μl (4 mM) CTP, and 20.5 μl of water, making a total of 50 μl. Well 2
contained 0.5 μl (1U) PNP, 0.5 μl (0.03U) IPP, 10 μl (0.2 mM) MESG, 2.5 μl 20X reaction
buffer, 12 μl (7 mM) MgCl2, enzyme (variable), substrate (variable) and H2O to fill to a final
volume of 50 μl. A control with either no enzyme or substrate was made for each trial. The
separate wells were incubated for 30 min at room temperature. After 30 min, well 2 was
combined to well 1, and absorbance was recorded every 30 s at 360 nm for 30 min. The kinetic
data was exported to Excel and initial rates were determined by visual inspection (to ensure
<10% conversion) and linear regression. Michaelis-Menten and substrate inhibition equations
were fit by non-linear regression using the software R. R is a language and environment for
statistical computing and graphics.
9.2.4 Purification of CMP-AEP
5 mL reactions containing 1 μM Ari-PntC, 1 mM of AEP, 2 mM CTP, 7 mM MgCl2 and
50 mM Tris-Cl pH 8 were allowed to proceed for 1 hour at room temperature prior to removing
the enzyme through centrifugation in a 5 kDa ultracentrifugation tube. The flow-through was
injected on the FPLC over the 5 mL GE Hi-Trap™ Q FF anion exchange column into the mobile
phase A (25 mM ammonium bicarbonate pH 9) and eluted using a linear gradient of 0-70%
mobile phase B (25 mM ammonium bicarbonate + 1 M NaCl pH 9). Peak fractions pertaining to
the CMP-AEP product (measured at 280 nm) were collected and lyophilized to a dry solid. 20-25
mg of the lyophilized product was dissolved into 600 μl of D2O before subsequent 1H, 13C, and
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P experiments were performed. Phosphonoacetic acid was added as an internal standard for the
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P experiments.

9.2.5 Substrate, Metal, and Secondary substrate Characterization
1 mL reactions containing 1 μM of either Ari-PntC, Tde-PntC, or Spn-LicC, 1 mM of
substrate, 2 mM nucleotide secondary substrate, 7 mM of a divalent metal (listed under Results)
and 50 mM Tris-Cl pH 8 were allowed to proceed for 2 hours at room temperature prior to
removing the enzyme through centrifugation in a 5 kDa ultracentrifugation tube. The flowthrough was added to an NMR tube and 31P experiments were then performed after using a D2O
standard to properly lock the NMR signal. Phosphonoacetic acid was added as an internal
standard for the 31P experiments.
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9.2.6 Mutagenesis
PCR Forward and reverse primers were designed for a variety of single substitutions of
Tde-PntC and Spn-LicC residues. Primer sequences can be found in the Appendix I. A 100 μL
reaction mixture was then made for each of the species in order to amplify the gene. The reaction
mixture consisted of: 5 % DMSO, DI water, 10 mM dNTP mixture, 2x Taq buffer, Taq
polymerase, forward primer, reverse primer, and the species DNA. The reaction mixture was
then aliquoted into 8 separate 10 μL fractions in an 8 strip PCR tube strip. The 8 wells were then
put into a thermal cycler, set to the conditions that can be seen in Appendix I. Optimal annealing
temperature was determined using a temperature gradient PCR in order to determine which
temperature in a specific gradient allowed for the best amplification of the gene. In cases where a
temperature gradient was not used and an optimal annealing temperature was already known, the
Taq buffer was replaced with a 5X Phusion buffer and Phusion polymerase to replace the Taq
polymerase. These results were checked using gel electrophoresis. A 1% agarose gel was made
using 0.40 g of lab grade agarose, 40 mL of 1X TAE buffer, and 2 μL of 10 mg/mL ethidium
bromide. The preparation of 1X TAE buffer is listed in Appendix IV. After solidification of the
prepared gel, the 10 μL fractions of the PCR reaction mixtures were mixed with about 2 μL of
bromophenol blue dye. Each was loaded into a separate well in the gel, along with a final well of
about 5 μL of 1Kb plus ladder. Gels were run at 100 V for about 45 minutes. Images were
analyzed using ImageLab software and the Bio-Rad Gel Doc EZImager. Agarose gels were
examined under a LabNet UV transilluminator and desired bands were cut out using a blade.
From these excised gel slices, the DNA was extracted using the Promega Wizard SV Gel and
PCR Clean-Up System. Phusion polymerase has exonuclease activity that cuts out the overhang
of the DNA amplifications. An adenosine-tail was added to the extractions in order to create a
new overhang that would be required for complementarity of residues when performing a
ligation. This was done by mixing: 20 μL DNA, 1 μL Taq polymerase, 1 μL 10mM dNTP
mixture, 2.5 μL 10X Taq buffer, and 1 μL 50mM MgCl2. This reaction mixture was then cleaned
up using the Promega Wizard SV Gel and PCR Clean-Up protocol. The cleaned reaction mixture
was then run on a 1% agarose gel to ensure that the presence of the appropriately sized DNA
bands. The pGEM-T Easy vector was used to clone the amplifications to subsequently be used
for sequencing. The cleaned gel extract of DNA was ligated into the pGEM vector using the
following reaction mixture: 3 μL DNA, 1 μL pGEM-T Easy vector, 5 μL 2X Rapid Ligation
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buffer, and 1 μL T4 DNA ligase. Positive controls were created by replacing the DNA with 2 μL
Promega control DNA, and negative controls were created by replacing the DNA with 3 μL
sterile water.
E. coli DH5α competent cells were prepared as explained in Appendix IV. Aliquots of 150
μL were thawed on ice, and then either the ligation reaction mixture or about 2-4 μL of miniprepped DNA directly were added to the thawed competent cells. The negative (no DNA added)
and positive controls (DNA from ligation kit added) were transformed in the same manner as the
ligation. The microcentrifuge tubes were then left on ice for 20 minutes and then heat shocked
for 2 minutes at 42°C. 1 mL of LB broth was then added to the mixtures, after which they were
sealed tightly and incubated at 37°C and 220 rpm for one hour. The transformation mixtures in
the tubes were then spun down in a microcentrifuge for one minute, and all but 100 μL of the
supernatant was poured off. The pellet formed was resuspended in the remaining supernatant and
plated directly on XCI LB-agar plates, containing 100 μg/mL carbenicillin, 0.5 mM IPTG, and
80 μg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside(X-Gal). Plates were then left to
incubate overnight (approximately 12 hours) at 37°C. Refer to Appendix IV for preparation of
LB broth and LB-agar plates. A single colony from the transformation plates were picked using a
sterile pipette tip and grown in a 3 mL culture containing 6 μL of ampicillin or kanamycin. The
cultures were left to grow overnight. The PureYield Plasmid Miniprep System was used to
isolate the recombinant pGEM plasmid that was then digested with NdeI and XhoI using the
following mixture: 2 μL DNA, 2 μL10X FastDigest green buffer, 1 μL NdeI, 1 μL XhoI, and 14
μL nuclease-free water. This mixture was incubated at 37°C for about one hour. To confirm the
presence of inserts of the correct size, the mixtures were run on a 1% agarose gel and imaged, as
described previously. The gel extraction protocol previously described was used to excise bands
of the correct size from the digest. Additionally, if a plasmid of the correct size was identified,
about 300 ng of the recombinant pGEM plasmid was added to sterile water to make a solution
totaling 7 μL to prepare the sample for sequencing.
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10 Results
10.1 Expression and Purification of Ari-PntC, Tde-PntC, and Spn-LicC
Ari-PntC

Tde-PntC
75 kDa
50 kDa

37 kDa

25 kDa

In

Re

FT

W1

W2

PP

Un In Re FT W1 W2 PP
Spn-LicC

37 kDa
25 kDa

W1

W2

PP

Figure 11. SDS-PAGE gel images of the Ari-PntC, Spn-LicC and Tde-PntC proteins after IMAC
purification. Ari-PntC and Spn-LicC are visible at the correct and expected size of 31 kDa and Tde-PntC at
69 kDa. The lanes from the IMAC purification are labelled as follows: Uninduced fraction (Un), Induced
fraction (In), Raw extract (RE), Flow through (FT), Wash 1 (W1), Wash 2 (W2), and Purified Protein
(PP).

The plasmid stocks of pET29-Spn-licC, pET29-Ari-pntC, and pET21-Tde-pntC were made
previously during the research conducted by Kissa Batul (Spn-LicC/Ari-PntC) and Jacqueline
Whiteside (Tde-PntC) and used in this research. The ari1348 and spn-licC genes were ligated
into a pET-29a vector, and the tde1415 gene was ligated into a pET-21b vector. These stocks
were used to express the protein in BL21 competent cells, and then purified using IMAC and
anion exchange chromatography through an FPLC system. The gel images after running SDSPAGE to confirm expression and determine purity can be seen in Figure 11. Typically, the Ari36

PntC and Spn-LicC constructs will yield approximately 5 g/L of protein in a 1 L culture, whereas
the Tde-PntC construct can yield upwards of 45 g/L. Both proteins were desalted using a PD-10
column and further purified via anion exchange chromatography prior to activity tests, the results
are seen in Figure 12.
1

2

3

M

75 kDa
50 kDa
37 kDa

25 kDa

Figure 12. SDS-PAGE of Spn-LicC (lane 1), Tde-PntC (lane 2), Ari-PntC (lane 3), and Bio-Rad Precision Plus
Protein Standard (lane M).

10.2 1H, 13C, and 31P NMR Identification of CMP-AEP Product
NMR analysis was employed in order to verify the hypothesized CMP-AEP product from
the putative phosphonate-tailoring pathway. Mass spectrometry data was also gathered to support
that the hypothesized structure was accurate. The results are seen in Figure 13. To solidify this
finding, 1H,

13

C, and 31P spectra of the product were obtained and compared to the standard 1H

spectrum of the related CDP-choline product. The CMP-AEP structure, along with the three
spectra and associated coupling constants are displayed in Figures 14-16. After acquiring a
sufficient 1H,

13

C, and

31

P spectrum, the resulting chemical shifts and coupling constants were

compared to the standard spectra of CDP-choline. From the similarities drawn between the
spectra of the two enzymatic products, and the previously gathered mass spectrometry data, it
can be concluded that CMP-AEP is the correct product of the putative phosphonate-tailoring
pathway that includes Ari-PntC and Tde-PntC.
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m/z
Figure 13. HR-ESI-MS of CMP-AEP from the Ari-PntC reaction revealing the [M-H]- ion at m/z 429.0582
consistent with a molecular mass of 430.0655 for molecular formula C11H20N4O10P2 (calculated 430.0655).
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Type, Atom Position

J (Hz)

7.95

Doublet, 1H, H6

7.6

6.12

Doublet, 1H, H5

7.6

6.00

Doublet, 1H, H1’

4.0

4.824.18
3.29

Multiplet, 5H, H2’, H3’, H4’, H5’

-

Multiplet, 2H, H2”

-

2.15

Multiplet, 2H, H1”

-

Figure 14. 1H NMR (D2O, 400 MHz) spectra of CMP-AEP from the Ari-PntC reaction:  7.95 (d, 1H, H6, J = 7.6 Hz), 6.12
(d, 1H, H5, J = 7.6 Hz), 6.00 (d, 1H, H1’, J = 4.0 Hz), 4.82-4.18 (m, 5H, H2’, H3’, H4’, H5’), 3.29 (m, 2H, H2”), 2.15 (m, 2H,
H1”).
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1
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Figure 15. 13C NMR (D2O, 100 MHz) spectra of CMP-AEP from the Ari-PntC reaction:  166.1 (C4), 157.7 (C2), 141.3
(C6), 96.6 (C5), 89.3 (C4’), 82.5 (C1’), 73.9 (C3’), 69.3 (C2’), 64.8 (C5’), 35.1 (C2’’), 26.1 (C1’’; 1JCP = 130 Hz).
Bottom spectrum represents commercial AEP alone.
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Figure 16. 31P NMR (D2O, 121 MHz) spectra from the Ari-PntC reaction of (A) CMP-AEP alone and (B) with
phosphonoacetic acid (PnAc) and 2-ethylaminophosphonate (AEP). Using PnAc as the internal standard with a
reported chemical shift of 15.7,5 our measured chemical shifts of CMP-AEP:  11.4 (PA), -11.4 (PB), 3J = 25.6
Hz.
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10.3 Substrate, Metal, and Secondary substrate Characterization
A variety of substrates were tested on all three proteins from this study. These substrates
include aminomethylphosphonate (AMP), phosphoethanolamine (PEA), glyphosate, taurine, 1amino-1-methylpropyl phosphonic acid, 3-phosphonopropanoic acid, phosphonoacetic acid, and
the newly synthesized methyl and ethyl phosphonate azides (synthesized by Edward Schmidt,
WLU). Figures 17-20 present the
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P spectra for the substrates that exhibited activity for each

enzyme, the other substrates did not exhibit activity. Figure 21 displays the reactions with the
preferred CTP secondary substrate, as well as ATP and GTP as alternate secondary substrates.
Aside from CTP, only ATP with Tde-PntC displayed detectable activity, while reactions with
GTP showed no activity.

Figure 17. 31P NMR (121 MHz) spectra of the reaction mixture without substrate or enzyme. The 2 mM CTP
secondary substrate is responsible for the observed peaks.
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Tde-PntC Reaction with PEA
Side Product

PEA

Product

Product

Tde-PntC Reaction
with AMP
Side Product

AMP

Product

Figure 18. 31P NMR (121 MHz) spectra of the Tde-PntC reaction with PEA and AMP (9.0 ppm). New peaks are
observed adjacent to the doublets at -5 and -10 ppm for the PEA reaction, and at -5.4 ppm for the AMP reaction. 1hour reactions of 10 µM PntC enzyme with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and 7 mM MgCl2,
pH 8.0. Side product is hypothesized to be pyrophosphate.
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Ari-PntC Reaction with
PEA
Side Product

Product

Product

PEA

Ari-PntC Reaction with
AMP
Side Product

Product

AMP

Figure 19. 31P NMR (121 MHz) spectra of the Ari-PntC reaction with PEA and AMP (9.0 ppm). New peaks are observed
adjacent to the doublets at -5 and -10 ppm for the PEA reaction, and at -5.5 ppm for the AMP reaction. 1-hour reactions of 10
µM PntC enzyme with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and 7 mM MgCl2, pH 8.0. Side product is
hypothesized to be pyrophosphate.

Spn-LicC Reaction with
EtAz Substrate

Side Product
Product

Product

EtAz

Figure 20. 31P NMR (121 MHz) spectra of the Spn-LicC reaction with the synthesized Ethyl Azide (EtAz) phosphonate substrate
(17.2 ppm). New peaks are observed adjacent to the doublets at -5 and -10 ppm. 2.5-hour reactions of 10 µM Spn-LicC enzyme
with 1 mM substrate and 2 mM of CTP in 50 mM Tris-Cl and 7 mM MgCl2, pH 8.0.
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Figure 21. 31P NMR analysis of 1-hour reactions of 10 µM PntC enzyme with 1 mM AEP and 2 mM of CTP,
ATP, or GTP in 50 mM Tris-Cl and 7 mM MgCl2, pH 8.0. The reactions with the preferred CTP secondary
substrate shows activity for both Ari-PntC and Tde-PntC. The Tde-PntC reaction with ATP showed some
activity. No activity was seen using GTP as a secondary substrate.
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From the variety of potential substrates tested, only those closely resembling AEP in structure
seemed to show activity with the three enzymes. AMP differs from AEP by only one carbon
atom, and PEA is almost identical to AEP but does not possess the direct carbon to phosphorus
bond seen in phosphonates. Table 2 compares the structures of all the substrates used in this
research. Spn-LicC has previously been shown to exhibit activity with PEA14. The most
interesting finding was the ability of Spn-LicC to utilize the EtAz substrate, as this substrate has
many potential applications and lays the foundation for future research. The other two proteins
did not seem to possess the ability to utilize the azide substrate, which is most likely due to
differences in the protein structures and sterics. Using data from the crystal structures of SpnLicC and Tde-PntC, protein cavity volumes were calculated to evaluate the effects of steric
restriction against the larger PCho substrate in the Tde-PntC active site. The larger pocket
volume of Spn-LicC (~381 Å3) compared to Tde-PntC (~287 Å3) corresponds to the difference
of ~64 Å3in molecular volume between CDP-Cho and CMP-AEP, indicating that the overall
cavity volume may hinder the variety of substrates these proteins can utilize.
Of the two non-preferred secondary substrates tested, Ari-PntC showed no activity with either
ATP or GTP, and only ATP allowed for Tde-PntC to exhibit activity. GTP showed no activity
for either enzyme. Spn-LicC was not characterized in this manner as other literature has already
explored the ability for Spn-LicC to utilize alternate nucleotide secondary substrates. The
findings were similar as no other nucleotide secondary substrate allowed for Spn-LicC to exhibit
activity, however ATP allowed for activity at a level which was 0.25% that of the activity seen
with CTP14. TTP and UTP have not yet been tested as potential alternate secondary substrates
with Ari- and Tde-PntC.
A variety of divalent metals (excluding lithium) were also tested to determine if any of the
three proteins would function without the preferred catalytic Mg2+ cations present. These metals
include: Zn2+, Co2+, Mn2+, Fe2+, Cu2+, Ca2+, and Li+. None on the listed metals allowed for proper
function of the enzymes and often caused the proteins to precipitate out of solution. This is not
surprising as all three proteins possess catalytic Mg2+ sites in the overall protein structure and it
is already known that metals such as calcium inhibit enzymes like Spn-LicC.
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10.4 Kinetic Analysis using the EnzChek® Pyrophosphate Assay
Kinetic trials have been performed for Ari- and Tde-PntC as well as Spn-LicC (Kissa
Batul, WLU) using the coupled pyrophosphate assay and various substrates. Using these
substrates, plots that feature the fitted Michaelis-Menten curve have been constructed. These
plots are presented in Figure 22. From these plots, kinetic parameters and constants were
determined and are presented and contrasted against other literature values in Table 1. Ari-PntC
possessed a Km value of 11.6 ±1.3 μM for AEP, and a kcat value of 3.66 ± 0.12 s-1. Tde-PntC
possessed a Km value of 15.5 ± 5.1 μM, and a kcat value of 1.05 ± 0.05 s-1. Spn-LicC with the
preferred PCho substrate exhibited a Km value of 2.36 ± 0.65 μM, and a kcat value of 1.06±0.04
s-1 4. Kinetic rates and constants for the alternate substrates are seen in Table 1.
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Figure 22. Steady-state kinetic analysis of cytidylyltransferase activities of (A) Spn-LicC with AEP, (B) SpnLicC with PCho, (C) Ari-PntC with AEP, (D) Ari-PntC with PCho, and (E) Tde-PntC with AEP. Activity not
detected for Tde-PntC and PCho. Error bars show standard errors. Kinetics for Spn-LicC were gathered by Kissa
Batul. All other kinetics were completed by Kyle Rice. Figure created by Dr. Geoff Horsman.
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Table 1. Summary of kinetic constants and rates for three cytidylyltransferase enzymes.
a

b

Standard errors are included for data generated in this work. Substrate inhibition observed with K = 3.99±1.13
S

c

d

mM. Substrate inhibition observed with K = 6.36±0.89 mM. ND, not determined due to low activity.
S

.

10.5 Preliminary Mutagenesis Work
Mutagenesis experiments were performed on the Spn-LicC and Tde-PntC enzymes as the
structure of both of these constructs has already been solved through crystallization. The overall
aim was to make 14 mutants based off of the crystal structures and multiple sequence
alignments, 7 for each protein. These would include 5 single substitution mutants for each
protein, and 2 double substitution mutants for each protein. The goal of this mutagenesis work
was to observe the versatility of each mutant protein to use uncommon substrates and determine
if the mutations allowed for increased activity compared to trials with the native proteins, in
addition to gaining information regarding the mechanisms of the proteins, what residues are
essential and what residues can be exploited to allow the proteins to accept uncommon
substrates. The amino acid and base pair sequences, primer sequences, multiple sequence
alignments, agarose gels, and DNA ladder reference can be found in the Appendices.
After successful synthesis of the K23A, D105N, D105E, D192N, and D192E single
substitution mutants for Spn-LicC, each was attempted to be ligated into the pGEM-T Easy
vector. Only the K23A, D105N, and D105E mutants were successfully ligated and cultured. The
sequencing of these three mutants to confirm the mutation is present is currently underway. Once
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all the mutants have been confirmed, the two double substitution mutants can be formed (D105N
+ D192N and D105E + D192E). The Tde-PntC mutants were generated next and the agarose
gels of those PCR reactions are shown in Appendix II.
Further mutagenesis work is currently underway in order to complete the remaining
mutants for Tde-PntC. These mutations include the full single mutants of E196D, E196N, and
E104N, as well as the E196D +E104D and E196N+E104N double mutants. The adenosine
overhang will also need to be added to these constructs in order to prepare for ligation into the
pGem-T Easy vector. The single mutants will need to be sent away for sequencing to confirm the
correct mutations are present before forming the double mutants.

11 Discussion
Although ~5% of sampled microbes encode phosphoenolpyruvate mutase (Ppm)6 and
bioinformatic studies within the Horsman group have identified nucleotidyltransferases in over
two-thirds of phosphonate biosynthetic gene clusters, including direct fusions to ~60% of Ppm
enzymes (Figure 5), phosphonate biosynthesis and biology remain poorly understood.17 There is
even less known about the nucleotidyltransferases associated with the biosynthetic pathways
responsible for forming cell-surface phosphonoglycans and phosphonolipids, despite the fact that
molecules such as PCho are known virulence factors encoded by the Lic pathway in pathogens
such as Streptococcus pneumoniae

12,31

. The research presented here focuses on two

phosphonate-specific cytidylyltransferases associated with these pathways and modifications that
have never before been characterized or documented in literature. Ari-PntC from the grampositive actinobacterium A. rimae and Tde-PntC from the gram-negative spirochete T. denticola.
Due to the lack of knowledge surrounding these biosynthetic pathways and the associated
enzymes it is difficult to draw direct comparisons from a wide variety of other proteins, however,
the findings presented here aim to highlight the gap between current biosynthetic knowledge and
future discovery potential. Understanding the biosynthetic logic of these modifications represents
an important goal with therapeutic implications and sets the stage for probing diverse
phosphonyl tailoring pathways, which will hopefully motivate continued investigation of
biological phosphonates.
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11.1 1H, 13C, and 31P NMR Identification of CMP-AEP Product
In order to confirm the hypothesis that CMP-AEP is the molecular product of the
reactions catalyzed by Ari-PntC and Tde-PntC, NMR analysis and mass spectrometry was
employed. Identifying the enzymatic product of these reactions was the first step towards
elucidating the catalytic mechanisms and residues operating within these proteins. This allowed
for conclusions and comparisons to be drawn about the steric interactions within these two
enzymes and the canonical Spn-LicC enzyme that are discussed further below. This knowledge
is useful in understanding the differences in ability to utilize various substrates as well as the
differences that exist in enzymatic rates and efficiency among all three proteins.
Figure 13 displays the HR-ESI-MS of CMP-AEP from the Ari-PntC reaction which
reveals the [M-H]- ion at m/z 429.0582, consistent with a molecular mass of 430.0655 g/mol for
the molecular formula C11H20N4O10P2. The incredibly similar masses between the predicted
molecule and actual molecule after isolation was the first indication that the proposed CMP-AEP
molecule was most likely the true enzymatic product. In order to confirm the exact structure of
the phosphonate molecule, 1H,

13

C, and

31

P NMR analysis was undertaken. Figure 14 displays

the 1H NMR spectrum of CMP-AEP from the Ari-PntC reaction. The chemical shifts and
coupling constants are as follows:  7.95 (d, 1H, H6, J = 7.6 Hz), 6.12 (d, 1H, H5, J = 7.6 Hz),
6.00 (d, 1H, H1’, J = 4.0 Hz), 4.82-4.18 (m, 5H, H2’, H3’, H4’, H5’), 3.29 (m, 2H, H2”), and
2.15 (m, 2H, H1”). Comparison to the structurally similar molecule and enzymatic product of
Spn-LicC, CDP-Choline, as well as the AEP starting material alone provided good evidence that
the CMP-AEP product was formed. These trials were repeated for the Tde-PntC product which
showed an identical spectrum. Figure 15 shows the 13C NMR spectrum of CMP-AEP from the
Ari-PntC reaction. The chemicals shifts and coupling constants are as follows:  166.1 (C4),
157.7 (C2), 141.3 (C6), 96.6 (C5), 89.3 (C4’), 82.5 (C1’), 73.9 (C3’), 69.3 (C2’), 64.8 (C5’),
35.1 (C2’’), 26.1 (C1’’; 1JCP = 130 Hz). Figure 16 displays the 31P NMR spectrum from the AriPntC reaction of CMP-AEP alone and also with phosphonoacetic acid and AEP included for
reference. Using PnAc as the internal standard with a reported chemical shift of 15.7,5 the
measured chemical shifts of CMP-AEP were as follows:  11.4 (PA), -11.4 (PB), 3J = 25.6 Hz. It
is believed that the doublets viewed in the

31

P spectra are a result of phosphorus-phosphorus

coupling due to the two phosphorus atoms in close proximity within the CMP-AEP structure.
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Once again, comparisons were made to the similar CDP-Choline molecule and AEP starting
material, and the experiments were repeated using the product of the Tde-PntC reaction which
yielded identical spectra. Based on the overall NMR spectra and resulting chemical shifts and
coupling constants, as well as comparison to structurally similar molecules, it was concluded that
CMP-AEP is the enzymatic product of Ari-PntC and Tde-PntC. These results clearly
demonstrate the Ari-PntC and Tde-PntC formation of CMP-AEP, and imply shared biosynthetic
logic for PCho and phosphonate tailoring pathways.
Although a mechanistic hypothesis regarding the formation of CMP-AEP was already
proposed prior to the confirmation of the CMP-AEP product identity, these findings only further
reinforce that hypothetical mechanism. Figure 23 outlines the proposed mechanism of

Figure 23. Proposed mechanism of PntC. (A) Electron density (Fo-Fc, 3.0 sigma) for the Tde-PntC:CMP-AEP
complex, highlighting interactions with phosphate in the site thought to be occupied by the PPi leaving group.
(B) Mechanistic interpretation of the crystallographic data. The proposed ternary complex structure (top) with
extensive interactions stabilizing the PPi leaving group of CTP (blue). Nucleophilic attack of AEP (green)
generates a pentacoordinate phosphate intermediate or transition state possessing additional negative charge
stabilized by Lys25 (middle). Loss of PPi generates the CMP-AEP product bound in the active site (bottom) as
seen in the crystal structure in (A). Figure created by Dr. Geoff Horsman.
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CMP-AEP formation in Tde-PntC, and the crystal structure that was previously solved displays
the CMP-AEP product within the protein3. A similar mechanism is expected for Ari-PntC,
although a crystal structure has yet to be completed and solved. The confirmation of the CMPAEP product supports this mechanism and further analysis of the crystal structure and proposed
mechanism allowed for conclusions to be made as to which residues to mutate in order to gain
more insight into this pathway. The Lys25 residue is evidently important catalytically, and the
first assumption made was that neutralization of this residue would lead to loss of function in the
protein. This is due to the essential function this residue performs in which it stabilizes the
additional negative charge generated in the pentacoordinate phosphate intermediate or transition
state formed during nucleophilic attack of AEP in the active site (Figure 23). Further
conclusions and hypotheses of the catalytic residues and mutations are discussed below in the
discussion.

11.2 Substrate, Metal, and Secondary substrate Characterization
In order to gain further insight into the versatility of these phosphonate-activating
cytidylyltransferases, a variety of substrates, divalent metals, and nucleotide secondary substrates
were utilized to determine if enzymatic activity could still be detected. As previously stated,
these substrates included AMP, PEA, glyphosate, taurine, 1-amino-1-methylpropyl phosphonic
acid, 3-phosphonopropanoic acid, phosphonoacetic acid (Table 2), and the newly synthesized
methyl and ethyl phosphonate azides. Of these substrates tested, only the AMP, PEA, and azide
molecules were accepted and allowed for enzymatic activity to be detected.

31

P NMR was used

to detect activity, as the appearance of new peaks not seen in the reaction mixture shown in
Figure 17 indicate that a new phosphorus-containing molecule has been formed. Figures 18-20
show the new peaks that have formed with the mentioned substrates, however, further
experimentation and isolation of the enzymatic products would need to be undertaken in order to
determine the molecular structure. It is not surprising that the AMP substrate was utilized by AriPntC and Tde-PntC, as this molecule is smaller than the cognate AEP substrate by only one
methylene group, nevertheless it indicates that both of these enzymes are able to accommodate
smaller molecules into the active site without any issues related to steric hindrance or overall
charge. PEA was another substrate that was predicted to be suitable for these enzymes. PEA is
almost identical to the preferred AEP substrate and is larger only by an inserted oxygen atom that
separates the characteristic carbon-phosphorus bond seen in the AEP phosphonate molecule. In
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addition, many studies have already shown the ability of cytidylyltransferases like Spn-LicC and
to utilize PEA as a substrate2,14,32, and many bacteria use this molecule to decorate the cellsurface12 to help protect the bacteria from cationic antimicrobial peptides (CAMPs) due to the
associated positive charge of the amino groups creating repulsion. The ability to use these same
substrates between the three enzymes suggests that the overall mechanism of CMP activation by
these proteins is similar, and that the active sites must share some unique features that allow for
this versatility. Glyphosate was an important substrate in these experiments due to the threat it
poses on the environment, specifically to soil and plant life. Glyphosate is found in many
commercial herbicides and any long-lasting negative effects on the ecology of soil and
groundwater systems is not completely known. Glyphosate does not breakdown readily and
tends to persist in these environments, reducing the quality of soil and the ability for new plant
growth to occur during crop rotation. This is especially devastating to those in the agricultural
industry and to the beneficial microorganisms that exist in the soil and contribute to healthy crop
growth.33,34 By identifying bacteria that possess the ability to act on the glyphosate molecules as
substrates, certain species could be introduced to an affected environment to act on the
glyphosate, aiding in effectively braking down or altering it enough to allow for removal by
other means. Unfortunately, Ari-PntC, Tde-PntC, nor Spn-LicC displayed any ability to use
glyphosate as a substrate. Other phosphonate molecules such as 1-amino-1-methylpropyl
phosphonic acid, 3-phosphonopropanoic acid, and phosphonoacetic acid (Table 2) were also
tested to determine if these enzymes could act on molecules that differed much more in structure
from the AEP substrate than the AMP and PEA molecules. Once again, no activity was shown
for these potential substrates, which is most likely accounted to steric hindrance and molecular
charge causing clashes in the active site of each protein.
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Table 2. Structural comparison of all substrates tested.

Structure

Phosphoethanolamine
(PEA)

1-amino-1-methylpropyl
phosphonic acid

Aminomethylphosphonate
(AMP)

3-phosphonopropanoic
acid

Aminoethylphosphonate
(AEP)

Phosphonoacetic acid

Glyphosate

Taurine

The most promising finding of these experiments was the activity shown by Spn-LicC to
utilize the newly synthesized phosphonate ethyl azide substrate shown in Figure 20. The
structure of the methyl and ethyl phosphonate azide substrates can be seen in Figure 24 below,
although the methyl azide did not allow for activity in any of the three enzymes. The purpose for
using this substrate is related to the practice of click chemistry. Click chemistry has become a
growing practice in recent years and is incredibly useful in the detection, localization, and
qualification of biomolecules. Click reactions are able to occur in one pot and do not generate
A)

B)

Figure 24. Chemical structure of the methyl (A) and ethyl (B) phosphonate azide substrates synthesized by
Edward Schmidt (WLU).
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harmful byproducts, and thus this practice has evolved to become part of many live cell
experiments in which researchers can use small molecular probes to attach to specific targets
within the cell and allow for non-invasive detection of specific features. One of many known
click chemistry reactions occur via strain-promoted azide-alkyne cycloaddition (SPAAC).
Although there are other click chemistry reactions that pertain to the use of azide-containing
molecules, the SPAAC reaction and principles have been used to investigate new ways of
identifying pathogenic bacteria by tagging specific biomolecules and glycoconjugates35,36. Based
on these principles, the ethyl azide substrate was synthesized in order to act as a potential target
for click chemistry reactions. Since the ultimate fate of the CMP-AEP and CDP-Choline
enzymatic products is to be exported to the bacterial cell surface and presented on biological
features such as the teichoic acids, these molecules have sufficient exposure to the environment
and are not contained within a cellular membrane. If the phosphonate ethyl azide substrate could
be utilized by these cytidylyltransferases enzymes it is simple to hypothesize that these
molecules would be exposed to the external environment. This would present an optimal
opportunity to utilize click chemistry and target the azide molecules, allowing for any bacteria
that present this substrate to be identified. Gaining a fast and efficient way of identifying various
bacteria that utilize a similar biosynthetic pathway to the proteins presented in this research has
many beneficial implications due to the pathogenic nature of the bacteria that possess a CMPactivating biosynthetic pathway. In theory, this would allow for rapid identification of possible
pathogens by supplementing bacterial cultures with a phosphonate ethyl azide nutrient capable of
crossing the cellular membrane and reaching the cytidylyltransferase responsible for activating
the substrate. The azide would eventually be presented on the bacterial cell-surface and reactions
such as the SPAAC reaction could be employed to locate and detect the azide molecules being
presented. Studies are currently underway in the Horsman group in which a method of screening
is being developed to rapidly detect different bacterial species that can utilize and present these
substrates, alluding to potential pathogens and furthering the little knowledge that exists about
phosphonate biosynthesis and phosphonate-tailoring machinery. Thus, the activity displayed by
Spn-LicC to utilize these azide substrates is promising and lays the foundation for many future
experiments with beneficial applications.
The metal and secondary substrate characterization was performed to help reinforce the
proposed biosynthetic mechanism of CMP-AEP formation as well as the evidence gathered from
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the crystal structures of Spn-LicC and Tde-PntC that show specific Mg2+ and CTP binding sites.
It was already assumed from analysis of these crystal structures and conserved residues that
reactions with non-preferred metals and secondary substrates would exhibit little to no activity,
as other research regarding cytidylyltransferases and the Spn-LicC enzyme specifically did not
conclude any significant activity and often reported inhibition of the enzymes by alternate
metals2,11,14. Of the several divalent metals tested (Zn2+, Co2+, Mn2+, Fe2+, Cu2+, Ca2+, Li+) none
displayed activity with any of the three proteins. In fact, many of these metals caused the
proteins to precipitate out of solution, suggesting that the enzymes were somewhat denatured and
altered by the presence of these metals, enough so that the enzymes precipitated out of solution.
In normal atmospheric conditions and at room temperature, the three enzymes are very stable.
Even after performing reactions and leaving the proteins to sit in solution for extended periods of
time did not cause any sort of precipitation. This suggests that magnesium plays an important
role in coordinating the active site of each protein during reactions, and other divalent metals
cannot be used to replace magnesium due to the stability it provides to the protein. Calcium did
not cause precipitation of the protein, however activity was still not seen using this metal. This
result was expected as literature already documents the inhibition of Spn-LicC in the presence of
calcium, and a previous colleague had already tested this result on the same protein and
concluded the same findings4,11. Experiments were performed on Ari-PntC and Tde-PntC merely
to satisfy the hypothesis that all three enzymes function using a very similar mechanism and that
all three enzymes require magnesium as a catalytic metal that appears to be irreplaceable.
The secondary substrate characterization was performed in order to determine the
versatility of the CTP binding site seen in the crystal structure of Spn-LicC and Tde-PntC.
Although all three enzymes studied are cytidylyltransferases, meaning that the CTP nucleotide
and cytidine are characteristic of this type of enzyme, slight activity has been demonstrated
before in experiments that replace CTP with other nucleotides. Figure 20 displays a series of
reactions that were analyzed using 31P NMR in which ATP and GTP were used to replace CTP
in reactions catalyzed by Ari-PntC and Tde-PntC. From this figure it is evident that the only
activity exhibited was by Tde-PntC with ATP. Tde-PntC is a bifunctional protein, with one
domain catalyzing interconversion of PnAA and AEP, and the other domain catalyzing the
reaction of AEP to CMP-AEP. The transamination reaction utilizes PLP as a secondary
substrate, and thus possesses the appropriate binding sites for this secondary substrate. Although
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activity was shown using ATP as a secondary substrate for the formation of product, it is not
known where within the protein ATP is able to bind to. However, the nucleotide secondary
substrate must be in close proximity of the AEP substrate in order to facilitate the reaction and
form CMP-AEP so it is hypothesized that the ATP in this reaction was able to fit in the binding
site where CTP would normally bind. This statement is supported by the research reported by
Rock et al.14 in which Spn-LicC was able to utilize ATP as a secondary substrate, and express
activity at a rate that was 0.25% of what was typically seen using CTP. Since Spn-LicC is not a
bifunctional enzyme and does not possess separate secondary substrate binding domains, it is
evident that ATP is able to fit somewhat into the usual CTP binding site to facilitate the reaction,
albeit at a much slower rate of catalysis. It is interesting that ATP (larger purine) binds but not
TTP (small pyrimidine like CTP). GTP showed no activity for either enzyme. No other
nucleotide secondary substrates were tested, and it is hypothesized that no activity would be
displayed by Ari-PntC or Tde-PntC with other nucleotides as the work by Rock et al.14 has
shown that Spn-LicC does not show activity with TTP or UTP. Overall, the similarities that are
seen when comparing the versatility of Ari-PntC and Tde-PntC to Spn-LicC suggests that the
two phosphonate-tailoring enzymes must share a very similar mechanistic pathway and protein
structure to the canonical enzyme. A figure of the multiple sequence alignment for these proteins
can be seen in Appendix V.

11.3 Kinetic Analysis using the EnzChek® Pyrophosphate Assay
To further support the research completed by previous colleagues and reinforce the
finding that Ari-PntC and Tde-PntC belong to a specific phosphonate-tailoring gene cluster,
kinetic analysis was undertaken to determine the enzymatic rates and compare differences
between the preferred phosphonate substrate and a variety of alternate substrates. Previous
kinetic analysis of the Ari-PntC enzyme had concluded that the ari1348 gene rightfully belongs
to a biosynthetic gene cluster responsible for phosphonate activation, due to the preferential use
of AEP over PCho and the location within the genomic neighborhood that encodes AEP
production and biosynthetic machinery associated with cell wall glycans such as LicD-like
(PntD) phosphotransferases or glycosyltransferases. Tde-PntC, however, had not yet been
characterized kinetically although it was hypothesized that the tde1415 gene also belonged to a
gene cluster associated with phosphonate tailoring due to the surrounding gene neighborhood,
including the bi-functionality of the protein, which encodes phosphonate biosynthesis. Spn-LicC
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has been characterized kinetically in literature from various sources14,37,38, and also by a previous
colleague4. Activity was observed for each enzyme with its proposed substrate, and a comparison
of substrate preference further supported the cognate substrate assignments of either AEP or
PCho. The results were compared to the rates reported for the canonical Spn-LicC enzyme and
Ari-PntC enzyme, however Tde-PntC has no direct comparisons to be made to other literature
values and was contrasted with the rates of Ari-PntC and Spn-LicC. This research states the very
first report of enzymatic activity and kinetic rates for the Tde-PntC cytidylyltransferase.
In order to facilitate the kinetic analysis, the EnzChek® pyrophosphate coupled assay
was used to detect pyrophosphate release

39,40

. The initial rate measurements of Spn-LicC

towards PCho with saturating concentrations of CTP from the research by Batul4 revealed a kcat
of 1.06±0.04 s-1 and KM of 2.36±0.65 µM, yielding a kcat/KM of 4.47x105 M-1s-1, comparable to
previous reports

14,37,38

. The Michaelis-Menten kinetic curves and overall kinetic rates are

displayed in Figure 22 and Table 1, respectively. In contrast, AEP as a substrate produced a kcat
value of 0.723±0.054 s-1, a KM value of 318±129 µM, and a kcat/KM of 2.27x103 M-1s-1 revealing a
200-fold preference for PCho over AEP. Ari-PntC exhibited the opposite preference, with a 440fold higher specificity constant for AEP versus PCho. Ari-PntC possessed a KM value of 11.6
±1.3 μM for AEP, a kcat value of 3.66 ± 0.12 s-1, and a kcat/KM of 3.15x105 M-1s-1. With PCho,
Ari-PntC displayed a KM value of 1.00 ±0.83 μM, a kcat value of 0.718 ± 0.344 s-1, and a kcat/KM
of 7.18x102 M-1s-1. Similarly, Tde-PntC was not sufficiently active towards PCho to obtain
steady-state kinetic data, but activity towards AEP was similar to Ari-PntC. Tde-PntC with AEP
possessed a KM value of 15.5 ± 5.1 μM, a kcat value of 1.05 ± 0.05 s-1, and a kcat/KM of 6.77x104
M-1s-1. Overall, clear preference for AEP as a substrate supports assignment of the Ari-PntC and
Tde-PntC enzymes as phosphonate-specific cytidylyltransferases. Furthermore, indications of
substrate inhibition were observed through the reaction of Ari-PntC and Spn-LicC with PCho as
a substrate. This observation must be pursued further in order to solidify, as the PCho substrate
used to gather these kinetic rates was purchased in the presence of calcium. Although Chelex
resin was used to remove the calcium, it does not remove every trace of the metal, which may
contribute to the inhibition observed.
Ideally, it would be best to gather accurate kinetic data without the use of
spectrophotometric or colorimetric assays, such as through HPLC or NMR trials of the Ari- and
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Tde-PntC reactions. This type of analysis allows for direct detection of the product, which can be
monitored by the area under the resulting peak at succeeding time points during the reaction.
This type of detection avoids the error associated with indirect assays that introduce separate
chemical reactions and monitor the formation of a side product, as stoichiometric calculations do
not need to be taken into account when monitoring the product directly over HPLC. This allows
for the area under the product peak to be compared to a standard curve for quantification.
Previous attempts to gather enzymatic rates using HPLC were carried out by creating a standard
curve for the CMP-AEP product using standard concentrations of CDP-choline, and a new curve
was created for each type of column used in the HPLC machine.
The greatest obstacle that arose from using HPLC to gather kinetic data is that it was
difficult to separate the CMP-AEP product from the CTP secondary substrate, due to the
similarities in structure and overall charge. Consequently, a variety of stationary phases have
been tested in order to achieve this separation. To gain a quick understanding of how the analytes
in the enzymatic reactions would separate, a standard injection of CDP-choline and CTP were
injected over the column prior to running the enzymatic reaction. The mobile phase was adjusted
accordingly and if separation of the two standards was achieved then kinetic trials were
performed. Unfortunately, separation of the two standards had only been achieved using a
column that features an –NH2 stationary phase, allowing for weak anion-exchange capabilities,
but the column appeared to deteriorate very quickly. This deterioration led to poor
reproducibility in retention times of the two analytes and eventually the separation of the two
molecules was altogether eliminated, resulting in only one peak being detected. Various other
stationary phases have been utilized, including the C18 and PS C18 (slight positive charge
introduced to the resin), strong anion exchange (SAX), and Kinetex® F5 and C18 Polar phases.
Prior to switching the focus to the coupled assay, three separate –NH2 stationary phase columns
had been used, with each column exhibiting great initial separation capabilities, followed by
rapid deterioration. Poor separation and reproducibly have greatly hindered kinetic trials using
HPLC. Nevertheless, these kinetic trials will still be pursued in the future. Kinetic data gathered
in this fashion will reinforce the kinetic data acquired using the EnzChek® pyrophosphate assay,
and will provide a second source of kinetic data for the three cytidylyltransferases presented in
this research.
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11.4 Preliminary Mutagenesis Work
The preliminary mutagenesis work carried out in this research aimed to create 7 mutants
of both the Spn-LicC and Tde-PntC constructs. The goal of this work was to create mutants of
each protein that would allow for uncommon and non-preferred substrates to be accepted into the
active site and activated with a CMP moiety through the typical cytidylyltransferase-catalyzed
reaction. The amino acid residues altered were chosen specifically to alter the sterics of the
protein and neutralize the charge on specific residues, as the molecular determinants of
specificity in each enzyme are primarily steric. For example, to accommodate the smaller
substrate AEP into the larger active site of Spn-LicC (in comparison to Tde-PntC), the smaller
Asp105 and Asp192 residues will be mutated to the larger Glu residues. The opposite approach
applies to the mutations for Tde-PntC in attempt to accommodate the CDP-Choline substrate.
Once each mutant has been created and successfully ligated into a pET vector, expression tests
will be performed until the protein can be isolated. Protein purification will follow. It is
hypothesized that these mutants will be more accepting of non-preferred substrates due to the
increase or decrease in active site size, including PCho/AEP and other similar phosphonate
molecules. Moreover, these mutants will ideally increase the activity and efficiency for the azide
substrates. The mutants for Spn-LicC to be created are as follows: Asp105 to Asn (D105N),
Asp105 to Glu (D105E), Asp192 to Asn (D192N), Asp192 to Glu (D192E), and Lys23 to Ala
(K23A). The D105N + D192N and D105E + D192E double mutants will also be created. The
mutants for Tde-PntC to be created are as follows: Glu104 to Asn (E104N), Glu104 to Asp
(E104D), Glu196 to Asn (E196N), Glu196 to Asp (E196D), and Lys25 to Ala (K25A). The
E104N + E196N and E104D + E196D double mutants will also be created. These mutants were
selected after analyzing the crystal structure of each enzyme and comparing the conserved
residues through multiple sequence alignments. The first aim of this mutagenesis work was to
form mutants that would be accepting of either cognate substrate, AEP or PCho. The two
substrates clearly differ in size, and possibly in charge; the positive charge of the quaternary
amine of PCho does not necessarily occur at the primary amine of AEP. Nevertheless, few clues
exist from the Tde-PntC crystal structure, which reveals water, Glu196, and Glu104 positioned to
interact with the primary amine of AEP via hydrogen bonds. Comparing the structures of the two
proteins revealed that the equivalent positions in Spn-LicC (D192 and D105) are occupied by
smaller Asp side chains. A comparison of the active sites in each enzyme is presented in Figure
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25. The smaller Asp side chains in Spn-LicC, in comparison to the Glu residues in Tde-PntC,
may be more accommodating of the larger PCho substrate. This may also explain why Tde-PntC
did not show detectable activity towards PCho as a substrate versus the smaller AEP cognate
substrate. Thus, reducing the size of the active site in Tde-PntC by changing the Glu residues to
Asp may allow more room to accept the larger PCho substrate, without altering the overall
charge present in the active site. Alternatively, reducing the size of the Spn-LicC active site by
mutating the Asp residues to Glu may be more accommodating of the smaller AEP substrate.
In order to understand the effect of charge neutralization in the active site, each enzyme
will also undergo mutation in which the Asp or Glu residues are mutated to Asn. The size of
each residue will remain similar, but the overall negative charge will be neutralized. Protein
structure simulations and multiple sequence alignments that include the Ari-PntC enzyme have
revealed that Ari-PntC possesses the same aromatic residues as Spn-LicC, which function to bind
the choline quaternary amine via cation-π interactions. This suggests that charge may not be a
key determinant of PCho versus AEP selectivity, and that Ari-PntC is more closely related to
Spn-LicC than Tde-PntC. To solidify this finding, the Asn residues are being introduced to both
Tde-PntC and Spn-LicC to observe if any changes to the enzymatic activity are presented, and if
neutralizing the charge in the active site will lead to a change in preference for either cognate
substrate.
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Figure 25. Structural comparisons of Tde-PntC (top) and Spn-LicC (bottom) showing representative
conformations from molecular dynamics simulations. (A) Tde-PntC active site with cognate ligand CMP-AEP
and magnesium ions colored teal; non-cognate ligand CDPCho and magnesium ions are colored magenta. (B)
Spn-LicC active site showing the cognate ligand CDPCho and magnesium ion colored magenta; non-cognate
ligand CMP-AEP and magnesium are colored teal. Figure by Dr. Geoff Horsman.

The mutations replacing Lys23 of Spn-LicC and Lys25 of Tde-PntC with Ala will be
compared to the findings observed in similar cytidylyltransferase enzymes in which the same
conserved Lys residue was mutated to Ala41,42. Mutations of this nature have been reported to
abolish activity of the enzymes completely, and it is hypothesized this will also occur with SpnLicC and Tde-PntC, which will support the relatedness of these cytidylyltransferases and
strengthen the finding that these conserved Lys residues are catalytically essential to the proteins.
In Tde-PntC, the terminal Lys25 of the consensus sequence is positioned to interact most
strongly with the magnesium-coordinated -phosphate of CTP, which appears to be positioned
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to accept additional negative charge arising during a pentacoordinate transition state, which
would result from nucleophilic attack of AEP.
In addition to allowing both Tde-PntC and Spn-LicC to be more accepting of both
cognate substrates, each mutant will be tested towards the methyl and ethyl azide phosphonate
substrates to determine if activity is increased. These substrates will have many beneficial
applications if the enzymes are capable of activating each molecule so that the azide substrate
can be displayed on the cell surface through subsequent reactions. Once a true crystal structure of
Ari-PntC is obtained similar mutants can be created which will allow for comparison to TdePntC and Spn-LicC, and the azide substrates can be tested towards this cytidylyltransferase as
well.

12 Conclusion
The research presented here has provided a novel glimpse into the enzymatic mechanisms
and function of two unique cytidylyltransferase enzymes that had not previously been
characterized or documented in literature. Ari-PntC from the gram-positive actinobacterium A.
rimae and Tde-PntC from the gram-negative spirochete T. denticola have now been
characterized kinetically and the structure of the enzymatic product has been confirmed. AriPntC possessed a KM value of 11.6 ±1.3 μM for AEP, a kcat value of 3.66 ± 0.12 s-1, and a kcat/KM
of 3.15x105 M-1 s-1. With PCho, Ari-PntC displayed a KM value of 1.00 ±0.83 μM, a kcat value of
0.718 ± 0.344 s-1, and a kcat/KM of 7.18x102 M-1s-1. Similarly, Tde-PntC was not sufficiently
active towards PCho to obtain steady-state kinetic data, but activity towards AEP was similar to
Ari-PntC. Tde-PntC with AEP possessed a KM value of 15.5 ± 5.1 μM, a kcat value of 1.05 ± 0.05
s-1, and a kcat/KM of 6.77x104 M-1s-1. Overall, clear preference for AEP as a substrate supports
assignment

of

the

Ari-PntC

and

Tde-PntC

enzymes

as

phosphonate-specific

cytidylyltransferases. These values were compared to literature and values acquired previously
for the canonical Spn-LicC cytidylyltransferase of S. pneumoniae. The enzymatic product of AriPntC and Tde-PntC was confirmed to be the hypothesized CMP-AEP product through NMR
analysis and mass spectrometry. Characterization related to the versatility of these proteins
indicated that only substrates similar in molecular size and composition were able to be utilized
by the enzymes, and that magnesium is most likely the only catalytic metal that the
cytidylyltransferases can accommodate. CTP is also the preferred nucleotide secondary substrate,
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with ATP indicating very low levels of activity with Tde-PntC. These results, in combination
with the protein crystal structures, have led to the conclusion that the molecular determinants of
specificity in each enzyme are primarily steric. This prompted the beginning of mutagenesis
experiments in which key residues conserved among various cytidylyltransferases will be altered
in order to attempt to accommodate non-cognate substrates within the active site and allow for
CMP activation of the molecules. One of these non-cognate substrates would be the newly
synthesized ethyl azide phosphonate molecule, which has been shown in this research to be
utilized by the Spn-LicC enzyme through NMR analysis.
Further research into this project will aim to create mutants of the Tde-PntC and SpnLicC constructs which will be more accepting of non-preferred substrates, specifically the ethyl
azide phosphonate substrate. By using this substrate as a target for molecular probes, a method
can be developed to quickly screen a variety of bacteria for similar cytidylyltransferase enzymes
and phosphonate biosynthetic machinery. It is expected that PntC enzymes will activate a variety
of phosphonates to furnish a mosaic of cell surface phosphonate chemistry. Identifying CMPconjugates will enable discovery of new phosphonyl modifications and elucidation of the
biological roles. The implications of this research aimed to improve the understanding of a
unique class of enzymes, some of which have not yet been studied or characterized until now,
and to gain knowledge of the unique cell-surface modifications that evidently possess a
relationship with virulence. More examples of related chemical logic in biosynthetic pathways
will present opportunities to understand and manipulate enzyme selectivity for developing
biocatalysts and selective antivirulence agents.
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14 Appendices
14.1 Appendix I – Protein and Primer Sequences
DNA sequence for Tde-PntC
ATGATTAAGCAAGCGGTGATTCTGGCGGGTGGCCTGGGTAGCCGTCTGAAGGATAAGACCAAGACCA
TGCCGAAGGGTTTTCTGGAGATCGGTGGCACCGCGATTGTTGAACAGAGCGTGCAAAAGCTGCTGGCG
CACGGTATCGAAAAAATCGTTATTGGTACCGGCCACTGCAACGAGTACTATGACAACCTGGCGAAGAA
ATACCCGGCGATCATTACCGTGAAGAACGAAAACTATGCGAACACCGGTAGCATGGGCACCCTGGAA
GTGTGCGCGAGCTTCGTGAACGAAAGCTTTCTGCTGCTGGAGAGCGACCTGATCTACGATAGCGCGGG
TCTGTTTAGCCTGATCAACGACGAGCGTAAGAACCTGATTCTGGCGAGCGGTGCGACCAAAAGCGGCG
ACGAGGTTTATCTGGAGGCGGATGAAAAGAACTGCCTGACCGGCCTGAGCAAGAACCGTGATGCGCT
GAAAAACATCTTCGGCGAGCTGGTTGGTATTACCAAGCTGACCAAAAGCACCCTGGACAAGATGTGCG
CGTACGCGAAAATCCACCACAGCGATCTGCCGAAAATGGAGTATGAACACGCGCTGCTGGAAGCGGC
GAAGACCATCCCGGTTGCGATCAAACGTATTGAGTACTTTGTGTGGCGTGAGATTGACAACGAAGATC
ACCTGGAGATGGCGGTTAAGAACATCTATCCGCACATTGTGGAGAACGAAAAACTGCGTGCGGTTCGT
CGTGAAGTGCTGCTGAACCCGGGTCCGGCGACCACCACCGACAGCGTTAAGTATGCGCAGGTGAGCG
CGGATATCTGCCCGCGTGAGAAAGCGTTTGGCGACCTGATGCAATGGCTGTGCGATGAACTGAAACTG
TTCGCGCTGGCGAGCGAAACCAACCCGGACGAGTACGAAACCGTTATGTTCGGTTGCAGCGGTACCGG
CGCGGATGAAGTGATGGTTAGCAGCTGCGTTCCGGACACCGGCCGTCTGCTGGTGATCGATAACGGTA
GCTACGGCGCGCGTATGGCGAAGATCGCGGACATCTACAAGATCCCGATGGATATCTTCAAGAGCAGC
ACCTACGAACCGCTGGACCTGCAGAAACTGGAGGCGGAATTCGCGACCAAGAAATACACCCACCTGG
CGTGCGTGTATCACGAAACCACCACCGGTCTGCTGAACCCGCTGCACATCATTTGCCCGATGGCGAAG
AAATACGGCATGGTGACCATCGTTGATGCGGTGAGCGCGTATTGCGGTATGCCGATGGACCTGAAGAG
CCTGGGCATTGATTTTATGGCGAGCACCAGCAACAAAAACATCCAGGGTATGGCGGGTGTTGGCTTCG
TGATTTGCAACAAGGCGGAGCTGGAAAAGACCAAAGACTACCCGATGCGTAACTACTATCTGAACCTG
TATGATCAGTACGCGTATTTTGCGAAAACCCACCAAACCCGTTTCACCCCGCCGGTTCAGACCATGTAC
GCGCTGCGTCAAGCGGTTCTGGAAACCAAGCAGGAAACCGTGCAAAAACGTTACGAACGTTATACCG
CGTGCTGGAACATCCTGGTTGCGGCGATTAAGAAACTGGGTCTGAAGATGCTGGTGAAAGAGGAACA
CCAGAGCCACTTTATTACCGCGATCCTGGAGCCGGAAACCCCGAAGTACAGCTTCGAAGCGCTGCACG
ACTTTGCGGCGGAGCACAGCTTCACCATCTATCCGGGTAAACTGGGCAACATTGACACCTTCCGTATT
GCGAACATCGGCGATATTCAACCGGAGGAAATGCGTCGTTTTACCGTGAAGCTGAAAGAATACATGA
ATGGCATCGGCGTTGGCGTT

Amino acid sequence for Tde-PntC:
MIKQAVILAGGLGSRLKDKTKTMPKGFLEIGGTAIVEQSVQKLLAHGIEKIVIGTGHCNEYYDNLAKKYPAIITVK
NENYANTGSMGTLEVCASFVNESFLLLESDLIYDSAGLFSLINDERKNLILASGATKSGDEVYLEADEKNCLTGLS
KNRDALKNIFGELVGITKLTKSTLDKMCAYAKIHHSDLPKMEYEHALLEAAKTIPVAIKRIEYFVWREIDNEDHL
EMAVKNIYPHIVENEKLRAVRREVLLNPGPATTTDSVKYAQVSADICPREKAFGDLMQWLCDELKLFALASETN
PDEYETVMFGCSGTGADEVMVSSCVPDTGRLLVIDNGSYGARMAKIADIYKIPMDIFKSSTYEPLDLQKLEAEFA
TKKYTHLACVYHETTTGLLNPLHIICPMAKKYGMVTIVDAVSAYCGMPMDLKSLGIDFMASTSNKNIQGMAGV
GFVICNKAELEKTKDYPMRNYYLNLYDQYAYFAKTHQTRFTPPVQTMYALRQAVLETKQETVQKRYERYTAC
WNILVAAIKKLGLKMLVKEEHQSHFITAILEPETPKYSFEALHDFAAEHSFTIYPGKLGNIDTFRIANIGDIQPEEMR
RFTVKLKEYMNGIGVGV
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DNA sequence for Ari-PntC:
CATATGCATCATCATCACCATCATAGCAGCGGTGTTGATCTGGGCACCGAAAATCTGTATTTTCAGAGC
ATGGCTTGTGTAAAAGGTTCAAATGCCGAGAAGACCAATGCGATTATAATGGCGGCGGGATTGGGAA
CGCGCATGGCACCTCTCACCAAAACCACACCTAAGCCGTTGATTTCGGTCAACGGAACGCCGATGATT
GAAACGGTCATCAATGCGCTGGTTACGGCCGGCGTTGAGAGGATCTCTGTGGTTGTCGGGTATCTCAA
AGAGCAGTTTTGCTATCTTGAGGAGCGCTATCCGGCCGTAGTGCTTGTTGAGAACACGGAGTATTTGG
AGAAGAATAACATCTCATCAATATATGCCGCCGTTGACGTTCTTGAGCAGGGGGCTACGTTTATTTGC
GAGGCTGACCTGGTTATTTCAGATGAGCATATTTTCCAACCACGGCCTTCTCGGTCGTGCTATTTTGGC
CGTAAGTTTTCCGGCCATACGGGCGACTGGGTGTTTGACCTTGACGATTCGGGAAAGATTGTCCGAAT
CGGCAAAGGCGGCAGCGATACGTATGCCATGGTGGGACTGTCGTACTTCTCGGCACCGGATGCAAAGC
GTTTGGCACGGTTTATGCATGATGCCTACAAAGAGACCGGCCACGAGCAGCTCTTTTGGGATGATGTG
GTGAATAACCATATTGCCGAATTAGATCTTTCAATTCACCCCGTTGAGGCACAGCAAATTGCGGAGCT
TGATAGCGTTGCGGAATTGGCGGCGTTTGACCATGGCTACGTATATCTTTTGAGGAGTTAG

Amino acid sequence for Ari-PntC:
MACVKGSNAEKTNAIIMAAGLGTRMAPLTKTTPKPLISVNGTPMIETVINALVTAGVERISVVVGYLKEQF
CYLEERYPAVVLVENTEYLEKNNISSIYAAVDVLEQGATFICEADLVISDEHIFQPRPSRSCYFGRKFSGHTG
DWVFDLDDSGKIVRIGKGGSDTYAMVGLSYFSAPDAKRLARFMHDAYKETGHEQLFWDDVVNNHIAELD
LSIHPVEAQQIAELDSVAELAAFDHGYVYLLRS

DNA sequence for Spn-LicC:
CATATGGGTTCTTCTCACCACCACCACCACCACTCTTCTGGTCTGGTTCCGCGTGGTTCTCACATGAAA
GAAATCCGTGTTAAAGCGATCATCCTGGCGGCGGGTCTGGGTACCCGTCTGCGTCCGCTGACCGAAAA
CACCCCGAAAGCGCTGGTTCAGGTTAACCAGAAACCGCTGATCGAATACCAGATCGAATTCCTGAAAG
AAAAAGGTATCAACGACATCATCATCATCGTTGGTTACCTGAAAGAACAGTTCGACTACCTGAAAGAA
AAATACGGTGTTCGTCTGGTTTTCAACGACAAATACGCGGACTACAACAACTTCTACTCTCTGTACCTG
GTTAAAGAAGAACTGGCGAACTCTTACGTTATCGACGCGGACAACTACCTGTTCAAAAACATGTTCCG
TAACGACCTGACCCGTTCTACCTACTTCTCTGTTTACCGTGAAGACTGCACCAACGAATGGTTCCTGGT
TTACGGTGACGACTACAAAGTTCAGGACATCATCGTTGACTCTAAAGCGGGTCGTATCCTGTCTGGTGT
TTCTTTCTGGGACGCGCCGACCGCGGAAAAAATCGTTTCTTTCATCGACAAAGCGTACGCGTCTGGTG
AATTCGTTGACCTGTACTGGGACAACATGGTTAAAGACAACATCAAAGAACTGGACGTTTACGTTGAA
GAACTGGAAGGTAACTCTATCTACGAAATCGACTCTGTTCAGGACTACCGTAAACTGGAAGAAATCCT
GAAAAACGAAAACTAACTCGAG

Amino acid sequence for Spn-LicC:
MGSSHHHHHHSSGLVPRGSHMKEIRVKAIILAAGLGTRLRPLTENTPKALVQVNQKPLIEYQIEFLKEKGIN
DIIIIVGYLKEQFDYLKEKYGVRLVFNDKYADYNNFYSLYLVKEELANSYVIDADNYLFKNMFRNDLTRST
YFSVYREDCTNEWFLVYGDDYKVQDIIVDSKAGRILSGVSFWDAPTAEKIVSFIDKAYASGEFVDLYWDN
MVKDNIKELDVYVEELEGNSIYEIDSVQDYRKLEEILKNEN
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Primer sequences for Tde-PntC and Spn-LicC Mutants:
Protein
Spn-LicC

Mutation
NdeI Site
XhoI Site
Asp105 to Asn (D105N)
Asp105 to Glu (D105E)
Asp192 to Asn (D192N)
Asp192 to Glu (D192E)
Lys23 to Ala (K23A)

Tde-PntC

NdeI Site
XhoI Site
Glu104 to Asn (E104N)
Glu104 to Asp (E104D)
Glu196 to Asn (E196N)
Glu196 to Asp (E196D)
Lys25 to Ala (K25A)

Sequence
5’- CATATGaaagcgattattctggcggc
5’- CTCGAGgttttcgtttttcagaatttcttccagtttgcg
Forward = 5’- ggcgaacagctatgtgattaatgcggataactatctg
Reverse = 5’- cagatagttatccgcattaatcacatagctgttcgcc
Forward = 5’- ggcgaacagctatgtgattgaggcggataactatctg
Reverse = 5’- cagatagttatccgcctcaatcacatagctgttcgcc
Forward = 5’- gtggatctgtattggaataacatggtgaaagataac
Reverse = 5’- gttatctttcaccatgttattccaatacagatccac
Forward = 5’- gtggatctgtattgggagaacatggtgaaagataac
Reverse = 5’- gttatctttcaccatgttctcccaatacagatccac
Forward = 5’- cgaaaacaccccggcagcgctggtgcag
Reverse = 5’- ctgcaccagcgctgccggggtgttttcg
5’- CATATGattaagcaagcggtgattctggc
5’- CTCGAGaacgccaacgccgatgc
Forward = 5’- ctttctgctgctgaacagcgacctgatctac
Reverse = 5’- gtagatcaggtcgctgttcagcagcagaaag
Forward = 5’- ctttctgctgctggacagcgacctgatctac
Reverse = 5’- gtagatcaggtcgctgtccagcagcagaaag
Forward = 5’- ccgaaaatggagtataaccacgcgctgctggaag
Reverse = 5’- cttccagcagcgcgtggttatactccattttcgg
Forward = 5’- gaaaatggagtatgaccacgcgctgctggaag
Reverse = 5’- cttccagcagcgcgtggtcatactccattttc
Forward = 5’- gaccaagaccatgccggcgggttttctggagatc
Reverse = 5’- gatctccagaaaacccgccggcatggtcttggtc
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14.2 Appendix II - Agarose Gels from Preliminary Mutagenesis Experiments with Spn-LicC

Figure A1. Agarose gel images showing the results of PCR amplification for the single D105E mutation
fragments in Spn-LicC. The fragment of the protein containing the NdeI cut site is shown on the left (~320 bp),
the fragment containing the XhoI cut site is on the right (~500 bp).

Figure A2. Agarose gel images showing the results of PCR amplification for the single K23A mutation
fragments in Spn-LicC. The fragment of the protein containing the NdeI cut site is shown on the left (~75 bp),
the fragment containing the XhoI cut site is on the right (~735 bp).
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Figure A3. Agarose gel images showing the results of PCR amplification for the full single D105E (left) and
K23A (right) mutations in Spn-LicC. The bands are present at the correct size of approximately 774 bp.

Figure A4. Agarose gel images showing the results of PCR amplification for the single D105N mutation
fragments in Spn-LicC. The fragment of the protein containing the XhoI cut site is shown on the left, the
fragment containing the NdeI cut site is on the right.
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Figure A5. Agarose gel images showing the results of PCR amplification for the single D192E mutation
fragments in Spn-LicC. The fragment of the protein containing the XhoI cut site is shown on the left (~230 bp),
the fragment containing the NdeI cut site is on the right (~580 bp). The last lane on each gel represents the full
D105E (left) and K23A (right) mutations after performing the reaction to add the adenosine overhang and
prepare each mutant for ligation.

Figure A6. Agarose gel images showing the results of PCR amplification for the full single D105N (left) and
D192E (right) mutations in Spn-LicC. The bands are present at the correct size of approximately 774 bp.
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Figure A7. Agarose gel images showing the results of PCR amplification for the single D192N mutation
fragments in Spn-LicC. The fragment of the protein containing the XhoI cut site is shown on the left (~230 bp),
the fragment containing the NdeI cut site is on the right (~580 bp).

Figure A8. Agarose gel images showing the results of PCR amplification for the full single D192N mutation in
Spn-LicC. The bands are present at the correct size of approximately 774 bp.
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Figure A9. Agarose gel image showing the results of the full D105N, D192N, and D192E mutations (left to
right) after performing the reaction to add the adenosine overhang and prepare each mutant for ligation. The
bands are present at the correct size of approximately 774 bp.

Figure A10. Agarose gel images showing the results of PCR amplification for the single E104D mutation
fragments in Tde-PntC. The fragment of the protein containing the XhoI cut site is shown on the left (~1530 bp),
the fragment containing the NdeI cut site is on the right (~320 bp).
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Figure A11. Agarose gel images showing the results of PCR amplification for the single K25A mutation
fragments in Tde-PntC. The fragment of the protein containing the XhoI cut site is shown on the left (~1770 bp),
the fragment containing the NdeI cut site is on the right (~80 bp).

Figure A12. Agarose gel images showing the results of PCR amplification for the full single E104D (left) and
K25A (right) mutation in Tde-PntC. The bands are present at the correct size of approximately 1850 bp.
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Figure A13. Agarose gel images showing the results of PCR amplification for the single E196D mutation
fragments in Tde-PntC. The fragment of the protein containing the XhoI cut site is shown on the left (~1250 bp),
the fragment containing the NdeI cut site is on the right (~590 bp). The last lane on each gel represents the full
E104D (left) and K25A (right) mutations after performing the reaction to add the adenosine overhang and
prepare each mutant for ligation.
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14.3 Appendix III – Vector Charts and DNA Ladder

http://ecoliwiki.net/colipedia/index.php/pET-29a(%2B)
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https://www.novoprolabs.com/vector/V11022
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https://www.biobasic.com/1kb-plus-dna-ladder-ready-to-use
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14.4 Appendix IV – Various Chemical Recipes and Methods
Stock solutions:
A1. Preparation of 50 mg/mL carbenicillin stock solution:


Dissolve 200 mg of carbenicillin in 4 mL of water



Filter solution through a 0.22-micron filter



Transfer to micro-centrifuge tubes and store at -20 °C

A2. Preparation of 50 mg/mL kanamycin stock solution:


Dissolve 200 mg of kanamycin in 4 mL of water



Filter solution through a 0.22-micron filter



Transfer to micro-centrifuge tubes and store at -20 °C

A3. Preparation of 50 mg/mL X-Gal stock solution:


Dissolve 100 mg of X-Gal into 2 mL Dimethyl formamide



Transfer to micro-centrifuge tubes and cover with aluminum foil



Store at -20 °C

A4. Preparation of 10 mg/mL ethidium bromide solution:


Combine 1 g of ethidium bromide solid and 100 mL of water



Stir with magnetic stir bar for several hours



Wrap the jar in aluminum foil and store at 4 °C

A5. Preparation of 50 mg/mL ampicillin stock solution:


Combine 200 mg of ampicillin in 4 mL of water



Filter solution through a 0.22-micron filter



Aliquot into micro-centrifuge tubes



Store at -20 °C

A6. Preparation of 50% glycerol solution:


Combine 20 mL of glycerol with 20 mL of water



Store at room temperature
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A7. Preparation of 0.1 M IPTG stock solution:


Dissolve 1.2 g of IPTG into 50 mL of water



Filter through a 0.22-micron filter



Transfer to micro-centrifuge tubes and store at -20 °C

A8. Preparation of 1X TAE buffer:


121 g of Tris



28.6 mL of glacial acetic acid



50 L 0.5M EDTA solution (pH 8)



Combine and add water to a final volume of 1 L



Prepares 1 L of 25X TAE buffer



Dilute 40 mL of 25X TAE with water to a final volume of 1 L for a 1X TAE buffer



Store at room temperature

A9. Preparation of 2 mg/mL BSA stock solution:


Combine 2 mg of BSA low endotoxin with 1 mL of water



Store in micro-centrifuge tube at -20 °C

A10. Preparation of primer stock solutions (1 example):


Forward primer = 33.3 nmol, add 333 μL water



Reverse primer = 33.8 nmol, add 338 μL water



Vortex both solutions for 10 minutes



Combine 10 μL of each primer with 90 μL of water in micro-centrifuge tubes



Store at -20 °C

A11. Preparation of buffers for IMAC purification:
Cell lysis buffer:


Add 6.057 g Tris to beaker



Add 17.53 g of NaCl



Combine with 200 mL Milli-Q water, adjust pH to 8.0
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Fill to 1 L total with water



Store at 4 °C

Wash buffer:


Add 200 mL of Milli-Q water to beaker



Add 1.51 g Tris



Add 0.34 g of imidazole



Adjust pH to 8.0 with HCl



Top up to 250 mL with Milli-Q water



Store at 4 °C

Elution buffer:


Add 200 mL of Milli-Q water to beaker



Add 1.51 g Tris



Add 4.25 g of imidazole



Adjust pH to 8.0 with HCl



Top up to 250 mL with Milli-Q water



Store at 4 °C

A12. Preparation of SDS electrophoresis buffer:


15.1 g of 25 mM Tris base



94 g of 250 mM glycine



900 mL deionized water



50 mL of 10 % SDS



Combine and adjust final volume to 1 L



Stir for several hours with magnetic stir bar



Store at room temperature

A13. Preparation of LB:


Combine 2.5 g of LB broth powder with 100 mL water



Autoclave solution and store at room temperature
84

A14. Preparation of Agar:


Combine 2.5 g of LB broth powder and 1.5 g of agar powder



Add 100 mL water



Autoclave and store at room temperature

A15. Bradford Reagent


To prepare 250mL of Bradford reagent:



- Add 25 mg of Coomassie blue to a beaker



- Add 12.5% mL of 95% ethanol



- Add 25 mL of phosphoric acid



- Top up to 250mL with Milli-Q water

A16. Chelax Protocol


- Make 100 mM of Phosphocholine in 10 mL of Milli-Q water



- Make Chelax resin



- 2.68 g of chelax in 6.58 mL of Milli-Q water



- Add resin to column and allow to run through



- Add 10 mL of phosphocholine to the column, and collect the flow through



- Add 0.5 g of addition Chelax to the flow-through collect and stir gently for 1 hour



- After 1 hour, filter the sample and aliquot into small portions

B1. Pouring Plates:


Heat up solidified agar in microwave until solution is entirely liquid



Allow liquid agar to cool slightly, do not let solidify again



Add antibiotic directly to agar solution:
o For ICX: add 160 μL X-Gal, 200 μL carbenicillin, and 500 μL IPTG
o For kanamycin: add 500 μL of 50 mg/mL kanamycin stock solution



Gently swirl agar solution and pour into 6 sterile petri dishes



Pour enough solution to lightly cover the entire area of the plate



Perform in sterilization chamber and leave plates to solidify in chamber



Wrap plates in parafilm and store at 4 °C if not being used immediately
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B2. Making glycerol stock cultures:


Prior to performing a miniprep of a liquid bacterial culture



Combine 700 μL of culture with 300 μL of 50 % glycerol stock solution



Store culture at -80 °C

B3. Preparing DH5α competent cells:


Streak DH5α culture stock onto agar plate with no antibiotic



Let incubate at 37 °C overnight



Transfer colony to 2 mL of LB with no antibiotic and let incubate at 37 °C overnight



Inoculate into 100 mL of LB at 37 °C



Prepare TSS buffer:
o 0.25 g LB
o 1 g of PEG 8000
o 500 μL DMSO
o 0.1 g MgCl2•6H2O
o 6 mL H2O
o Combine and adjust pH to 6.5
o Adjust to final volume of 10 mL and autoclave buffer



Once OD at 600 nm reaches 0.4, transfer culture to two 50 mL culture tubes



Spin down cultures at 4000 rpm for 5 minutes



Resuspend cell pellets in 5 mL of TSS buffer each



Aliquot 200 μL of each solution into micro-centrifuge tubes



Micro-centrifuge tubes must be on ice and open flame must be present



Flash freeze all tubes in liquid nitrogen and store at -80 °C

B4. Preparing agarose gels:


Combine 0.6 g agarose powder and 60 mL TAE buffer



Heat in microwave until solution is clear



Allow solution to cool, do not let solidify



Add 2 μL of ethidium bromide, quickly swirl solution
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Pour solution gently into a plastic gel housing containing a well-comb



Remove air bubbles from gel



Let solidify for 20 minutes



Remove comb and place housing with gel in the electrophoresis chamber containing TAE
buffer

B5. Preparing gels for SDS-PAGE:


Using BioRad Kit and apparatus



Fasten two 0.75 mm glass plates to BioRad device



In a 50 mL beaker, combine:
o 2 mL Resolver A
o 2 mL Resolver B
o 2 μL tetramethylethylenediamine
o 20 μL 10 % ammonium persulfate



Slowly pipette the solution between the glass plates until the first green line



Top up the plates with deionized water and let sit for 20 minutes to polymerize



In a separate 50 mL beaker, combine:
o 1 mL Stacker A
o 1 mL Stacker B
o 2 μL tetramethylethylenediamine
o 10 μL 10 % ammonium persulfate



Pour off water from top of plates



Slowly pipette solution between the glass plates until 0.5 cm from the top



Insert comb of desired size



Let polymerize for 20-30 minutes



Remove comb and submerge in SDS buffer within electrophoresis chamber
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14.5 Appendix V – Multiple Sequence Alignments
A

AEP/ChoP binding
Metal coordination
Cytosine binding
Phosphate binding
Ribose binding
Apo salt bridge

B

Figure created by Dr. Geoff Horsman.
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